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ABSTRACT 
DESIGN AND INFERENCE IN PHASE II/III CLINICAL TRIALS 
INCORPORATING MONITORING OF MULTIPLE ENDPOINTS 
Herman E. Ray 
May 20,2011 
The phase II clinical trial is a critical step in the drug development process. 
In the oncology setting, phase II studies typically evaluate one primary endpoint, 
which is efficacy. In practice, a binary measurement representing the response to the 
new treatment defines the efficacy. The single-arm, multiple-stage designs are 
popular and the Simon 2-Stage design is preferred. 
Although the study designs evaluate the efficacy, the subject's safety is an 
important concern. Safety is monitored through the number of grade 3 or grade 4 
toxic events. The phase II clinical trial design based on the primary endpoint is 
typically augmented with an ad hoc monitoring rule. The studies are designed in 
two steps. First, the sample size and critical values are determined based on the 
primary endpoint. Then an ad hoc toxicity monitoring rule is applied to the study. 
Previous authors recommended a method to monitor toxic events after each 
patient is enrolled which is also known as continuous toxicity monitoring. A trial 
designed at the JG Brown Cancer Center combined the Simon 2-Stage design with 
continuous toxicity monitoring. We describe how to integrate the continuous 
toxicity monitoring methodology with the Simon 2-Stage design for response. 
vi 
Theoretical justification is given for the nominal size, power, probability of early 
termination (PET), and average sample size (ASN) of the combined testing 
procedure. A series of simulations were conducted to investigate the performance of 
the combined procedure. We discover that the type I error rate, type II error rate, 
PET, and ASN are subject to the correlation between toxicity and response. In fact, 
the study may have a smaller type I error rate than expected. 
The theoretical expressions derived to describe the operating characteristics 
of the combined procedure were utilized to create a new flexible, bivariate, 
multistage clinical trial. The design is considered flexible because it can monitor 
toxicity on a different schedule than response. An example is considered in which 
toxicity is measured after four equally spaced intervals and the response is evaluated 
only at the second and fourth toxicity examinations. This example corresponds to a 
data monitoring committee's meeting schedule that may happen every 6 months 
over a two year span.. The effect of the correlation on the type I and type II error 
rates is examined through simulation. The simulations also examine the power over 
the range of response rates with a fixed toxicity rate in the alternative region and 
vice-versa. 
There are several single-arm, multiple-stage clinical trial designs that 
consider multiple endpoints at the same time. A subset of the designs includes those 
that consider both efficacy and toxicity as binary endpoints. A common problem, 
considered after the conduct of the trial, is appropriate inference given the repeated 
examinations of the multiple endpoints. We propose a uniformly minimum variance 
unbiased estimator (UMVUE) for the response in a multistage clinical trial design 
incorporating toxicity effects. The proposed estimator and the typical maximum 
likelihood estimator (MLE) are evaluated through simulation. The estimator 
requires further modification when continuous toxicity monitoring is combined with 
a multistage design for response. The modified estimator maintains low bias over 
the range of possible response values. 
The larger phase lIb or phase III clinical trial is the logical extension of the 
Vll 
bivariate research based on exact calculations. The phase lIb or III clinical trials 
typically include an ad hoc toxicity monitoring rule ensuring participant protection. 
The designs also include provisions to allow early stopping for futility or efficacy 
utilizing group sequential theory or stochastic curtailment. We also examine a novel 
large sample clinical trial design that incorporates correlation between the response 
and toxicity events. The design uses the typical critical values associated with the 
standard normal distribution. It also searches for critical values specific to the 
global hypothesis associated with both response and toxicity. The bivariate test is 
then combined with efficacy and safety monitoring based on a flexible time-varying 
conditional power methodology. The type I and type II error rates of the bivariate 
test procedure, along with the bivariate test procedure combined with the 
conditional power methodology, are investigated through simulation. A modification 
is developed for the conditional power methodology to preserve the type I and type 
II error rates. 
In the end, the research extends the bivariate clinical trial designs in an 
attempt to make them more appealing in practice. Although, the research resulted 
in positive outcomes, additional work is required. 
Vlll 
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The practice of evaluating treatments in human subjects through a clinical 
trial is relatively new. Although it can be traced to the 18th century, much of the 
rigorous statistical work in the area of clinical trials has been conducted within the 
past 80 years (Friedman et al., 1998). Chow and Liu (2004) observe that many of 
the statistical advances are directly related to the implementation of regulations 
designed to protect human subjects that participate in the trials. 
The treatments under evaluation progress through phases in the drug 
development process (Friedman et al., 1998). Traditionally, there are four phases 
denoted as phase I, II, III, and IV. Each phase has a unique objective that is 
reflected in the clinical trial design. 
A phase I clinical trial is intended to provide the initial evaluation of a new 
treatment administered to human subjects. The studies attempt to determine 
metabolic and pharmacological activities of the treatment in humans, side effects of 
increasing dose, and early evidence of effectiveness (Chow and Liu, 2004). This 
initial information is required to design the subsequent phase II clinical study. The 
phase I designs are small, flexible studies that incorporate frequentist or Bayesian 
principles. In practice, the primary focus of the phase I study is patient safety 
(Chow et al., 2008) while the phase II trial is concerned with efficacy. 
The phase II clinical study is usually designed to test the efficacious 
attributes of a treatment that passed through a phase I study. The trials are often 
single-arm studies that test the clinical response rate against some pre-specified 
value, which represents the maximum response rate that is not clinically interesting 
1 
(Stallard et al., 2001). The clinical response rate (referred to as response rate) can 
consist of complete response (CR), partial response (PR), stable disease (SD), or 
progressive disease (PD) (FDA, 2007). Typically, the studies measure some 
combination of the different response rates, such as the sum of complete and partial 
response or objective response (OR). The designs typically incorporate multiple 
stages, or interim analyses. Green (2006) notes that most phase II trials incorporate 
two stages and the Simon 2-Stage design (Simon, 1989) is the most popular. 
The endpoint utilized in the comparative phase III study may be different 
than the endpoint used in the phase II study (Friedman et al., 1998). The 
comparative phase III studies can consider survival endpoints, as well as response 
rates. The designs often include provisions for early examination of the data using 
group sequential theory. The early methodologies by Pocock (1977), O'Brien and 
Fleming (1979), and many others allow early termination of the trial if there is 
evidence to reject the null hypothesis. Other authors, such as Emerson and Fleming 
(1989), consider group sequential procedures which allow the trial to terminate early 
in favor of or to reject the null hypothesis. Jennison and Turnbull (1999) refer to 
these designs as "inner-wedge" designs since the futility stopping boundaries form a 
wedge inside of the efficacy boundaries. The designs primarily focus on normally 
distributed variables, such as clinical response or event free survival. 
All clinical trials must also consider the safety of the trial's participants. 
Chow and Liu (2004) note that the ICH E9 guidelines on statistical considerations in 
clinical trials stress that safety must be monitored in all clinical trials (ICH, 1999). 
Therefore, procedures that allow for early termination of the trial for safety reasons 
should be considered. The patient safety is typically monitored through the number 
of grade 3 or higher toxicities experienced by the study participants. The toxicity 
grades are defined by the Common Toxicity Criteria (NCI, 2009). Our research 
focuses on phase II clinical trials that combine response and safety consideration. A 
trial designed at the .JG Brown Cancer is the motivation of the research. 
2 
1.1 Motivating Example 
The Simon 2-Stage design (Simon, 1989) was combined with the continuous 
toxicity monitoring (Ivanova et al., 2005) in an early single-arm phase II trial 
designed at the JG Brown Cancer Center. Despite the chemotherapy treatment, 
patients with multiple myeloma tend to relapse due, in part, to drug resistance. 
Essentially, the damaging effects of the chemotherapy on the myeloma cells can be 
counteracted by the nurturing bone marrow microenviroment. The ability to inhibit 
cellular repair would allow apoptosis to continue, thus rendering the treatment more 
effective. Simvastatin appears to overcome the cell-adhesion mediated drug 
resistances in ex vivo experiments. It is also known that zoledronic acid increases 
the effects of simvastatin. The principal investigator hypothesized that simvastatin 
combined with zoledronic acid will decrease bortezomib and bendamustine drug 
resistance when treating multiple myeloma patients. 
The life expectancy of patients with relapsed or refractory multiple myeloma 
is not very good. Therefore, the trial must be able to stop early if the combination 
treatment does not appear to be beneficial so the patients can be moved onto the 
standard treatment. The Simon 2-Stage design was employed to test the sustained 
response (SR) rate achieved on the new treatment plan against the corresponding 
sustained response rate derived from current literature. The SR is defined as either 
complete response, partial response, or stable disease. The new treatment will be 
rejected if the SR is 48% (or less) and accepted if it is 68% (or greater). The 
minimax design was selected with ar = 0.05 and (3r = 0.20. If there are 11 or more 
responses in the first 20 patients, then the study will acrue 40 total subjects. If 
there are 24 or fewer total responses from the 40 subjects, then the treatment will 
be rejected. 
The combination of the two cytotoxic agents could produce a large number of 
grade 3 or 4 toxic events very quickly. Therefore, we decided to monitor the number 
of toxic events after each patient is enrolled in the trial. The study could be 
terminated if there is sufficient evidence that the toxicity rate is greater than or 
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TABLE 1 
Boundaries for Toxicity Monitoring (PTo = 0.33, CtT = 0.05, n = 40,) 
Minimum Maximum # of Subjects 
# Subjects # Subjects with a Toxicity (bi ) 
4 4 4 
5 6 5 
7 7 6 
8 9 7 
10 11 8 
12 14 9 
15 16 10 
17 18 11 
19 19 12 
20 22 13 
23 23 14 
24 27 15 
28 28 16 
29 30 17 
31 32 18 
33 34 19 
35 37 20 
36 40 21 
equal to 33%. The probability of stopping early, if the true toxicity rate is less than 
33%, was fixed at Ctt = 0.05. The Pocock boundary (Pocock, 1977) was selected 
since it affords a greater probability of discontinuing the study early. Table 1 
reports the discrete toxicity boundary values. The cumulative number of toxic 
events after each person is treated will be compared to the boundary values. If the 
total number of grade 3 or higher toxicities, after person i is treated, is greater than 
or equal to the associated boundary value, bi , then the combination treatment is 
rejected for safety considerations. 
The motivating example identified the initial problem to be solved. The 
Cancer Center required a way to predict the effect of the continuous toxicity 
monitoring on the Simon 2-Stage design's operating characteristics. The expressions 
4 
are crucial to fully understand the effect the correlation has on the combined 
procedure since there is an underlying assumption of independence between the two 
endpoints. Chapter 2 contains a review of the current literature associated with the 
phase II clinical trial designs. Chapter 3 examines the theoretical derivations of the 
expressions for the operating characteristics of the combined procedure. Chapter 3 
also contains a thorough evaluation of the operating characteristics of the combined 
procedure. Chapter 4 expands the ad hoc design into a formalized phase II clinical 
trial design that considers response on a different schedule than toxicity. The design 
includes multiple examinations of response with the ability to continuously monitor 
toxicity. Inference after the conduct of the bivariate trial is considered in Chapter 5. 
The concept is expanded into the multiple-arm large sample phase IIb or III setting 




REVIEW OF MULTISTAGE CLINICAL TRIALS THAT 
INCLUDE MULTIPLE ENDPOINTS 
The motivating example combined two commonly used methodologies into in 
one ad hoc procedure. The Simon 2-Stage design (Simon, 1989) was utilized to 
design the trial based on the response criteria. Group sequential theory, along with 
exact calculations, were leveraged to determine the continuous toxicity boundary 
values. 
The Simon 2-Stage design is commonly used in the phase II setting. It is 
based on the binomial distribution and leverages work on phase II clinical trials 
based on exact calculations by Gehan (1961), Aroian (1968), Schultz, Nichol, 
Elfring, and Weed (1973), Colton and McPherson (1976), and Fleming (1982). Each 
author contributed a component to the development of two-stage designs. The 
result is a popular phase II clinical trial design that controls the type I error rate 
while allowing an examination of the data before the end of the trial. 
The continuous toxicity monitoring methodology relies on group sequential 
theory, which allows hypothesis testing to be performed after groups of patients are 
enrolled. The family of group sequential clinical trials are designed in such a way 
that the type I error rate is preserved while taking advantage of the sequential 
enrollment of the subjects. The same characteristics are utilized to monitor the 
cumulative number of toxicities while controlling the type I error, or the probability 
of declaring a safe treatment unsafe. 
The Simon 2-Stage design combined with continuous toxicity monitoring is 
an ad hoc design. The sample size determination is based only on response, even 
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though the inclusion of the toxicity monitoring affects the procedure's power to 
detect meaningful differences. There are phase II clinical trials that examine 
multiple endpoints simultaneously while allowing multiple examinations of the data. 
2.1 Phase II Bivariate Clinical '!rial Designs 
The phase II clinical trial is often a single-arm multistage clinical trial. The 
primary end point is typically defined to be a response rate, which is a predefined 
combination of complete response (CR), partial response (PR), stable disease (SD), 
or progressive disease (PD) (FDA, 2007). The studies are designed to test the 
response rate of the treatment against some pre-specified value elicited from the 
principal investigator or literature. The theoretical value represents the response 
rate under the best treatment currently available. 
The safety of the patients is also an important endpoint to consider. The 
safety is typically monitored through the number of grade 3 or 4 toxic events as 
defined by the Common Toxicity Criteria (NCI, 2009). There are two general ways 
to incorporate toxicity into the phase II clinical trial design. One method includes 
toxicity considerations through formal designs that accommodate multiple 
endpoints. It is also possible to utilize an ad hoc design in which the toxicity 
monitoring is developed outside of the design that considers the primary endpoint. 
The formal designs include the bivariate two-stage methodologies proposed 
by Bryant and Day (1995), as well as the multistage bivariate designs proposed by 
Conaway and Petroni (1995). The two competing designs rely on different theory to 
develop the procedures and expressions for the operating characteristics. The 
underlying execution of the designs is the same. First, a pre-defined number of 
subjects will be enrolled into the trial. If the number of responses is too low, or the 
number of toxicities is too high, then the trial enrollment is suspended. If not, then 
another group of subjects is enrolled. In the two-stage setting, if the number of 
responses is high, and the number of toxicities is low, then the treatment is declared 
successful. Otherwise, the treatment is declared unsuccessful since the response rate 
7 
is too low, or the toxicity rate is too high. Figure 1 displays the hypothesis space. 
The value, PRo, specifies the largest response rate that is uninteresting under the 
null, while PRA specifies the smallest response rate that is clinically meaningful. The 
toxicity rate, P To ' is the smallest toxicity rate that is unacceptable while PTA is the 
largest toxicity rate that is acceptable. The stage-wise sample sizes and critical 
values used to evaluate both response and toxicity are selected to ensure that the 






Figure 1. The Hypothesis Space Associated with Conaway and Petroni's Phase II 
2-Stage Bivariate Design 
The formalized bivariate designs have several issues that limit their utility. 
Some of the limitations have been addressed while others require additional research. 
The methods require specification of the odds-ratio, which relates the 
response to the toxicity. Tournoux et al. (2007) examine the effect of misspecifying 
the odds-ratio on the clinical trial. The type I error rate, or the probability of 
declaring an unsuccessful treatment successful, is affected by incorrect specification 
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of the odds-ratio. The Bryant and Day design is more robust against the actual 
odds-ratio being different than specified at the design. It is also possible to adjust 
the second stage sample size to reflect the odds-ratio based on data accrued in the 
first stage (Wu and Liu, 2007). 
Both designs assume that response and toxicity are equally important to the 
principal investigator. In reality, the principal investigator may allow for larger 
toxicity to achieve a larger response rate. Jin (2007) provides a bivariate clinical 
trial design that incorporates multiple stages, which also allows for tradeoffs 
between toxicity and response. 
The Conaway and Petroni design does not have readily available software to 
compute the sample sizes and critical values, which limits its utility. The Bryant 
and Day design does have supporting software, and is a more appealing choice. In 
practice, it appears that toxicity monitoring rules are developed outside of the 
clinical design utilized to evaluate the primary endpoint. In other words, the clinical 
trial is designed in two steps. First, the trial is designed to evaluate the primary 
endpoint, and then, the toxicity monitoring rule is put into place. 
Ivanova et al. (2005) provide an example of a stopping rule for safety that is 
included in an ad hoc manner. The trial will stop early if 13 or more of the first 20 
patients enrolled (nt) into an arm experienced a toxicity. The toxic event was 
defined as not being able to tolerate at least 2 courses of treatment. The stopping 
rule relies on the fact that the 
P {( # of Toxicities ) ~ 13 I Pro = 0.40, nt = 20} :S 0.05. 
There are instances when the new agent may cause severe toxicities that 
require continuous monitoring to ensure the participants' safety. Ivanova et al. 
(2005) provide an expansion of the stopping rule described above that can be 
applied to situations that require continuous toxicity monitoring. They suggest 
monitoring the cumulative number of toxic events after each patient is enrolled 
based on boundary values developed through group sequential theory. 
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The design is constructed in an ad hoc manner so that the odds-ratio, or the 
correlation between toxicity and response, is ignored at the design phase of the 
clinical trial. The total effect on the operating characteristics is also unknown, 
including the type I and II error rates. Exact formulas for the operating 
characteristics are vital for the designs to be a possible option. 
2.2 Inference After Bivariate Clinical Studies 
The principal investigator and others vested in the study require more 
information than just the determination that the treatment is successful (or not). 
The ability to create unbiased point estimates and associated confidence intervals 
after the conduct of a multistage clinical trial that includes multiple endpoints is 
also important. The estimates are required to evaluate the treatment. Further, 
these estimates are vital to designing future large phase lIb or III clinical trials. 
In the context of continuous variables, Jennison and Turnbull (1999) 
demonstrate that the maximum likelihood estimate (MLE) is bias due to the 
multi-modal distribution of the estimate resulting from multistage clinical trials. 
Jung and Kim (2004) note that the usual MLE utilized after the conduct of the 
Simon 2-Stage design is also bias due to the optimal sampling effect. The bias is 
created because we only observe extreme values resulting from crossing either the 
lower or upper boundary in the early stages. They discover a uniformly minimum 
variance unbiased estimate (UMVUE) that is applicable to the multistage phase II 
clinical trials based on exact calculations. 
There is only limited research in the area of point estimation following 
multistage, single-arm phase II clinical trials that incorporate multiple endpoints 
based on exact calculations. Chang (2009) develops a point estimator that is 
applicable in the situation but assumes that some of patients are not eligible for all 
possible responses. In this context, he proposes a MLE, which requires a special 
numeric algorithm called expectation-maximization (EM) method designed to 
handle data missing at random. 
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The point estimator proposed by Chang (2009) is for a specific situation and 
would likely need modifications to work in the Simon 2-Stage design combined with 
continuous toxicity monitoring. There is evidence to suggest that the traditional 
MLE will be biased in this setting as well. There is also some concern that ignoring 
the toxicity monitoring will cause an issue if the Jung and Kim (2004) point 
estimator is applied based solely on the response considerations. 
2.3 Large Sample Theory - Univariate Designs 
The motivating example combined the Simon 2-Stage design with the 
continuous toxicity monitoring methodology proposed by Ivanova et al. (2005). The 
continuous toxicity monitoring methodology relies on the group sequential theory 
that evolved from the truly sequential procedures developed for quality assurance 
proposes (Jennison and Turnbull, 1999). The group sequential procedures are 
usually employed in the phase III setting since they require larger sample sizes 
making normal approximations appropriate. 
An important aspect of protecting subjects is the ability to evaluate the data 
during the conduct of the trial. Patients are typically enrolled into trials 
sequentially, and the results are available in a similar manner. A naive approach is 
to repeat the standard significant test through the conduct of the trial. Armitage, 
McPherson, and Rowe (1969) observe that repeating the usual significant test as 
subjects are accrued will inflate the type I error rate. The authors also create a 
numeric integration algorithm for the multivariate normal distribution that is vital 
to future developments in group sequential theory. 
Pocock (1977) proposes a significant improvement over earlier sequential 
procedures with a closed group sequential procedure. The closed procedure has a 
maximum sample by which a decision will be made. This is a significant 
improvement over the open sequential procedures, which would continue to enroll 
subjects until a decision could be made. Pocock's methodology is based on the 
normal distribution and the calculations described by Armitage et al. (1969). The 
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Pocock procedure allocates equal type I error rate to each examination of the data. 
O'Brien and Fleming (1979) propose a similar design to the Pocock design except 
that the procedure allocates less type I error early in the conduct of the trial. Lan 
and DeMets (1983), as well as Slud and Wei (1982), introduce clinical trial designs 
that improve the methodologies proposed by Pocock, as well as O'Brien and 
Fleming (1979). A common limitation shared between the Pocock and the 
O'Brien-Fleming designs is the number and timing of the interim analysis must be 
determined during the design stage of the trial. Deviation from the initial plan will 
result in changes in the type II error rate. The Lan and DeMets design "spends" the 
type I error rate according to an alpha-spending function. The specific timing of the 
interim analysis does not need to be specified when the trial is designed, nor does 
the number of interim analysis. 
The theory and applications associated with group sequential theory 
progressed rapidly from the advent of the alpha-spending function. The traditional 
procedures only stopped early to reject the null hypothesis, but Pampallona and 
Tsiatis (1994), as well as Emerson and Fleming (1989), formulate "inner-wedge" 
clinical trial designs. The inner-wedge design allows the trial to stop early to reject 
or accept the null hypothesis. The designs work with other endpoints such as overall 
survival leveraging Cox's proportional hazards model (Cox, 1972), or the 
non-parametric Kaplan-Meier estimator (Kaplan and Meier, 1958). Wei, Su, and 
Lachin (1990) adapt the group sequential theory so the trials can incorporate 
repeated measurements on the subjects through generalized estimating equations 
proposed by Liang and Zeger (1986). 
Halperin et al. (1982) propose a method that allows a study to terminate 
early for futility based on stochastic curtailment, which is a flexible approach to 
monitoring the emerging results of a clinical trial. Lachin (2005) describes 
stochastic curtailment as a decision to terminate the trial based on an assessment of 
the conditional power (CP). CP is the conditional probability that the final result 
will exceed the critical value given the accrued data along with an assumption about 
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the data to be observed during the remainder of the study. Ying and Clarke (2010) 
outline a flexible time-varying conditional power boundary methodology that 
allocates portions of the type II error over time based on the typical alpha-spending 
functions. The methodology has similar benefits including the ability to either 
pre-specify the interim analysis, or use the flexibility associated with the 
alpha-spending approach to modify the exact timing of the interim analysis. The 
resulting methodology is an intuitive expansion and application of the conditional 
power approach to futility monitoring. 
2.4 Large Sample Theory - Bivariate Designs 
The large phase III clinical trials must also consider the safety of the 
subjects. The group sequential theory was extended to include multiple endpoints, 
such as toxicity and response. There are two basic ways multiple endpoints may be 
included into the design. 
The first general method reduces the multiple endpoints into a "global" test 
statistic such as the Hotelling's t-test (Hotelling, 1931), a X2 test, or an F test. 
Pocock, Geller, and Tsiatis (1987), as well as Tang, Gnecco, and Geller (1989), 
propose group sequential testing procedures based on O'Brien's generalized least 
squared statistics (O'Brien, 1984) designed to handle multiple endpoints. Jennison 
and Turnbull (1991) also developed a group sequential procedure based on exact 
calculations for the X2 and the F statistics. 
Although the global test statistic can handle multiple endpoints, in practice 
it may not be desirable to allow uncontrollable tradeoffs between toxicity and 
response. It is also possible to develop a test that considers the marginal hypotheses 
separately but rejection of all individual hypotheses is required to declare the 
treatment successful. Jennison and Turnbull (1993), as well as Cook and Farewell 
(1994), propose bivariate test procedures that considers both endpoints separately, 
but attempts to control the global type I and type II error rates. The group 
sequential procedures allow one to evaluate both efficacy and futility, as well as 
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patient safety, through the conduct of the trial. There are also more sophisticated 
methods proposed to control the type I error rate as well. Chuang-Stein et al. (2007) 
suggest a method that attempts to control the average type I error rate resulting in 
slightly different significant levels associated with the marginal hypothesis test. 
The procedures proposed by Jennison and Turnbull (1993), Cook and 
Farewell (1994), Chuang-Stein et al. (2007), and Kordzakhia et al. (2010) create a 
new multiple comparison issue referred to by Offen et al. (2007) as the reverse 
multiplicity problem. The typical multiplicity problem arises when a researcher 
evaluates multiple endpoints, but rejects the null hypothesis if any of the endpoints 
appear to be significantly different from the control. In this case, the significance 
levels for testing the individual endpoints are adjusted downward to account for the 
multiple analyses in order to conserve the overall type I error rate. There are many 
methods available, such as the Bonferroni correction, the Westfall and Young 
procedure (Westfall and Young, 1993), or the False Discovery Rate (Benjamini and 
Hochberg, 1995). 
The reverse multiplicity problem appears when we are required to show 
statistically significant differences on all co-primary endpoints. Depending on the 
number of co-primary endpoints required, and the correlations between them, the 
type II error rate of the study could be substantially inflated resulting in much less 
power than expected (Chuang-Stein et al., 2007). Often, the sample size is increased 
to control the type II error rate, but Chuang-Stein et al. (2007) demonstrate that 
the increase in sample size maybe very large. Offen et al. (2007) suggest reducing 
the multiple endpoints to one (or at least a minimal number). 
In Chapter 6, we propose a multiple-stage, group sequential trial that 
combines the flexible time-varying conditional power methodology proposed by Ying 
and Clarke (2010) with the customary multiple-endpoints fixed sample size method 
proposed by Jennison and Turnbull (1993). The result is a flexible multiple-endpoint 
group sequential procedure that preserves the type I and II error rates. 
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CHAPTER 3 
SIMON'S 2-STAGE DESIGN COMBINED WITH 
CONTINUOUS TOXICITY MONITORING 
The phase II clinical trial plays a critical role in the drug or treatment 
development process. It is used to ensure the new agent is sufficiently promising to 
warrant comparison to the current standard treatment in a large phase III study. 
Typically, the response rate, or the number of positive responses to the treatment, is 
used to determine if it is sufficiently promising for further investigation. The trials 
can be designed to accrue data in stages and perform an evaluation of the 
effectiveness of the treatment after each stage is complete. This design allows the 
experiment to be stopped early if the therapy does not appear to be beneficial, 
which prevents the continued administration of an ineffective treatment. Green 
(2006) observes that most Phase II trials usually employ two-stage designs, and the 
Simon 2-Stage design (Simon, 1989) is usually preferred. 
It is also important, and usually required, to monitor the safety of the 
patients over the course of the experiment. There are two basic ways to incorporate 
toxicity considerations into a trial design. The simpler method to implement is an 
ad hoc rule that stops the trial early if more than a specified number of toxicities 
occur. The second general methodology relies on theory that uses the bivariate 
statistic comprised of both the number of responses and the number of toxic events. 
Conaway and Petroni (1995), as well as Bryant and Day (1995), both create test 
that reject the agent if the number of responses is too low or the number of toxic 
events is too high. The Conaway and Petroni design can be extended beyond two 
stages but still examines the response and toxicity rates at the same time. 
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Ivanova et al. (2005) expands the ad hoc toxicity monitoring methodology so 
the toxic events can be monitored after each patient is enrolled, which is also 
referred to as continuous toxicity monitoring. The continuous toxicity monitoring 
can be combined with a single or a multiple stage evaluation of response, such as 
the Simon 2-Stage design. It is uniquely capable of monitoring toxic events when 
there is a concern the events will be severe while also allowing sufficient time for a 
measurable response to develop. In this chapter, we derive the operating 
characteristics of a trial that combines the Simon 2-Stage design with the 
continuous toxicity monitoring. The characteristics of interest include the 
probability of early termination, the size of the trial under the null hypothesis, and 
the average sample size. The motivation of the research is based on the practical 
application described in Section 1.1. 
3.1 Study Design 
The Simon 2-Stage design is one of the most popular designs used in phase II 
clinical trials. There are agents which can produce a large number of toxic events 
very fast which warrant continuous toxicity monitoring. Ray and Rai (2011a) 
provide an example of a combination treatment for patients with relapsed, 
refractory multiple myeloma. The treatment combines simvastatin and zoledronic 
acid to reduce mediated drug resistances with bortezomib and bendamustine. The 
combination of the cytotoxic agents may induce a large number of toxic events very 
quickly. They explore a procedure that combines the Simon 2-Stage design with the 
continuous toxicity monitoring, which will be referred to as the combined procedure. 
The combined procedure was used in the clinical trial designed to evaluate the new 
combination treatment. 
The combined procedure assumes the ith person can only experience one of 
the four possible outcomes at one time. The underlying theory assumes that X rti , 
where r indicates if a response occurred and t indicates if a toxic event occurred, 
follows a multinomial distribution with with parameters POO , POI, PlO , and Pll. A 
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response for the ith person is X Ri = X lOi + X lli and a toxic event is 
X Ti = XOli + Xlli. The probability of a response is denoted as PR = PlO + Pll while 
the probability of a toxicity is denoted as P T = POI + Pll. 
The methodology is implemented in two steps. First, the Simon 2-Stage 
design parameters are required which include specification of the desired type I and 
II error rates, as well as PRo and P RA . The value PRo is the largest response rate 
that is not clinically interesting while PRA is the smallest response rate that is 
clinically meaningful. Simon's 2-Stage procedure returns the first stage sample size, 
nl, the minimum number of responses required to continue onto the second stage, 
TI, the total sample size, n, and the total number of responses required to reject the 
null hypothesis, T. 
The next step is to determine the boundaries used to evaluate the cumulative 
number of toxicities experienced by the patients accrued up to that point. The 
information required to determine the boundaries include the maximum tolerated 
toxicity rate, the total sample size, n, and the probability of stopping the trial early 
if the true toxicity rate is less than or equal to the specified toxicity rate under the 
null hypothesis. The usual group sequential theory, including the integrals over the 
multivariate normal distribution, is leveraged to obtain the boundary values, 
{aI, a2, ... ,an}, associated with the standard normal test statistics. The original 
algorithms proposed by Armitage et al. (1969), as well as the algorithm proposed by 
Zhang and Rosenberger (2008), can be utilized to determine the boundary values. 
The resulting boundary values must be transformed so they can be used against the 
cumulative number of toxic events experienced after each patient is enrolled. The 
transformed boundaries will be denoted as {bl , b2 , ... ,bn }. It should be noted that 
the actual probability of stopping the trial early under the null hypothesis may be 
larger than specified after the boundary values are transformed. Jennison and 
Turnbull (1999) suggest tweaking the resulting boundaries to achieve the desired 
probability under the null hypothesis. 
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The trial can be conducted with the response and toxicity boundaries in 
place. The cumulative number of toxicities experienced after each patient is 
enrolled, from 1 to (nl - 1), is compared to the associated boundary values bl 
through bn1 -1. If the number of toxicities is at or greater than the associated 
boundary value, then the trial is stopped. Once nl patients are enrolled, then the 
total number of toxicities is evaluated against the boundary bn1 and the total 
number of responses is compared to the value rl. The study should be halted if 
either the number of toxicities is greater than (bn1 - 1) or if the number of responses 
is less than (rl + 1). If the trial continues, then the number of toxic events that 
occur after patients (nl + 1) through (n - 1) are assessed with the associated 
boundary values bn1+l through bn - l . If the number of toxic events is equal to or 
exceeds any of the associated boundary values, then the trial should be terminated. 
If the trial enrolls all n subjects, then the total number of responses and the total 
toxicities are evaluated against the response boundary, r, and the toxicity boundary, 
bn , respectively. If the number of responses is less than (r + 1) or if the number of 
toxicities is greater than (bn - 1), then the null hypothesis is not rejected. The 
appropriate conclusion is the new agent is not sufficiently promising. If the response 
is larger than the value r and the number of toxicities is less than the value bn , then 
the null hypothesis is rejected. Thus we can conclude that the new agent is 
sufficiently promising. 
3.2 Determine Stopping Boundaries for Continuous Toxicity Monitoring 
The Cancer Center required a method to produce the continuous toxicity 
monitoring methodology. First, we will discuss an algorithm to calculate the 
toxicity boundary values based on the usual group sequential theory. The general 
logic can be applied to the exact calculations described by Pocock (1977) or to the 
alpha-spending approach described by Lan and DeMets (1983). We will discuss the 
application of the logic to the alpha-spending approach since it allows greater 
flexibility. 
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In a manner similar to Jennison and Turnbull (1999), let {Zl, Z2, . .. , ZK} be 
a sequence of standardized test statistics associated with a group sequential test. 
Assume the sequence of test statistics have the following three properties 
1. (Zl, Z2,'" , ZK) is multivariate normal 
2. E(Zk) = eJ(h), k = 1,2, ... , K 
which is equivalent to saying that the sequence of standardized test statistics have 
the canonical joint distribution with information levels {II, h, . .. , IK } for the 
parameter e. Note that COV(Zi, Zj) = fi, 1 ~ i ~ j ~ K in the smiple setting. 
This also implies that the sequence {Zl, Z2, ... , ZK} is Markov. 
The sequence of probabilities 
P{ZI ~ all = a(tl) 
P{Z2 ~ a2, Zl < all = a(t2) - a(tl) 
can be constructed to calculate the boundary values, {all' .. , ak}, where a( ti ) is the 
alpha-spending function at time ti . The multi-dimensional integrals are typically 
evaluated through the recursive formulas using the methods developed by Armitage 
et al. (1969). The integration method is efficient but also somewhat cumbersome to 
implement in custom solutions. 
Zhang and Rosenberger (2008) present an alternative algorithm that is 
simpler to implement. Their methodology uses the correlation matrix and the 
integration methods developed by Genz (1992), which are available in both SAS and 
R. The correlation matrix is used to define the relationship between successive test 
statistics. The fact that R-! (Zl, Z2)' rv BV N(O, 1) is used to establish the required 
integral where R is the correlation matrix, Zl and Z2 are standardized test 
statistics, and I is the identity matrix. Then 
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(1) 
with p = corr(Zl' Z2), can be utilized to find the Pocock or the O'Brien-Fleming 
boundaries. The correlation can be specified to represent equal spacing of the 
interim analysis which results in boundary values equivalent to those produced by 
the ld98.exe software (Reboussin et al., 1998). 
Now, the total number of toxic events after each patient is enrolled will be 
compared to a corresponding boundary value. It is important to note that the 
algorithm produces boundary values, {aI, a2, ... aN}, associated with the normalized 
test statistics, (Zl' Z2, ... ,ZN), where N is the total sample size and 
n = 1,2,3, ... ,N is number of patients accrued. The values {aI, a2, . .. ,aN} must 
be transformed into the integer boundary values, {b1 , b2 , . .. ,bN }, for the results to 
be applied to monitoring of the number observed toxicities. The boundaries, 
{b1 , b2 , ... ,bN }, are calculated with the following formula 
(2) 
where i represents the ith observation in the sequence i = 1,2, ... ,N (Ray and Rai, 
2011a). The resulting size of the test using the integer values, {b1 , b2 , . .. ,bN }, 
maybe larger than the desired size of the test. Jennison and TUrnbull (1999) suggest 
modifying the resulting boundary values, {b1 , b2 , . .. ,bN }, to achieve the desired 
characteristics, including the type I error rate. Exact calculations described by 
Jennison and TUrnbull should be used to determine the type I error rate after the 
transformation. The choice of alpha-spending function will determine the operating 
characteristics of the trial or control the probability of stopping the trial early 
(I van ova et al., 2005). 
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3.3 Explanation of the Combined Procedure 
Suppose that the response and toxicity are both binary outcomes observed 
for each patient enrolled in the trial. The toxicity is continuously monitored after 
each patient is enrolled and the response is monitored according to a Simon 2-Stage 
design. The procedure is designed to stop early if there is significant evidence to 
accept either null hypothesis HlO or H20 , which are defined as 
HlO : PR ~ PRo versus HlA : PR > PRo 
and 
H20 : PT ~ PTo versus H2A : PT < PTo ' 
(3) 
The value PRo is the largest response rate that is not clinically interesting and PTo is 
the maximum tolerated toxicity rate. The Simon 2-Stage parameters will be 
denoted as rl, nl, r, and n. 
Let Xrti be the observation associated with the ith patient where r indicates 
if a response occurred and t indicates if a toxic event occurred. Then 
Xrti = (XOOi' X Oli , X lOi , X lli) follows a multinomial distribution with parameters 
Poo , POl, Ho, and Pn· A response for the ith subject is X Ri = X lOi + X lli and a 
toxic event is X Ti = X Oli + X lli . The probability of a response is PR = PlO + Pn 
and the probability of a toxicity is PT = POI + Pn. The data layout for the ith 
person is displayed in Table 2. Let Yrtm = 2::1 Xrti be the accumulated data up to 
and including the mth observation for r = 0, 1 and t = 0, 1. The total number of 
responses will be defined as YRm = 2::12::=0 X lti = 2::1 X Ri and the total 
number of toxicities will be YTm = 2::12:;=0 X r1i = 2::1 X Ti . The stages of the 
trial will be called m E {1, ... ,nl, ... , n} and include the Simon 2-Stage time 
periods in the sequence. This serves to simplify the formulas and the understanding. 
In a manner similar to that described by Jennison and Turnbull (Jennison and 
Turnbull, 1999), we define the Cm(YRm , YTmiPoo , POI, PlO , Pn) as the probability of 
reaching stage m with YRm responses and YTm toxicities given the underlying 
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TABLE 2 
Contingency Table for Response and Toxicity of the ith individual 
Toxicity 
No Yes 
Response No X OOk X Olk 
Yes X lOk X Uk X Rk 
probabilities Poo, POI, PlO , Pu· We will shorten it to Cm(YR, YTIP). Then define 
(4) 
For m :S nl, the formula to calculate the probability of stage m is 
(5) 
min(bm-l-l,YT) 
L Cm-1(r, tIP)f(YR - r, YT - t) (6) 
t=max(YT-l,O) r=max(YR-l,O) 
where bm is the boundary value associated with the continuous toxicity monitoring 
defined in Equation (2). The probability of reaching stage m = (nl + 1) is 
min(bm-l-l,YT ) 
Cm(YR, YTIP) = L Cm-1(r, tIP)f(YR - r, YT - t). (7) 
t=max(YT-l,O) r=max(YR-l,rl) 
Then the remaining probabilities (nl + 2) through n can be calculated with 
Equation 5. The probabilities of reaching stage (nl + 1) are slightly modified 
because the response boundaries are also imposed at stage nl, which reduces the 
probability of making it to stage (nl + 1) under the null hypothesis. In other words, 
the number of combinations available to progress into the next stage has been 
reduced by the inclusion of the response and toxicity boundaries. 
3.4 Properties of the Combined Procedure 
The calculations of the operating characteristics, once the probability of 
reaching stage m with YRm responses and YTm toxicities are determined, is similar 
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to the derivations described by Jennison and Turnbull (1999). 
The Cm(YR , YrIP) can be selected and summed to calculate the size and the 
probability of early termination (PET) under the null hypothesis. The probabilities 
of crossing the boundary at any stage m =f nl or n is 
m m 
7'm(P) = L L Cm(x, YiP). 
y=bm x=o 
At stage nl 
n1 7"1 
7' n1 (P) = L L Cn1 (x, yiP) 
y=bn1 x=o 
and at stage n 
n 7" 
7'n(P) = L L Cn(x, YiP). 
y=bn x=o 
Then the test procedures power function 1r(P) is 
n 
1r(P) = 1 - L 7'i(P). 
i=l 
The power function will determine the size of the test under the null hypothesis, 
and the power to detect differences under the alternative hypothesis. The 
probability of early termination is 
n-l 
PET(P) = L 7'i(P). 
i=l 
The expected sample size, or average sample size (ASN), can computed as 
n-l n-l 








The "+ 1" in the formula above is a direct consequence of not being able to stop at 
the first stage. Thus we are guaranteed to make it through the first stage, or we 
cannot stop the trial based on the experience of one patient. 
3.5 Simulations 
A series of simulations was conducted to evaluate the effect of the joint 
probability on the size and power of the combined procedure. The simulations 
23 
included various combinations of PRo, PRA , PTo , aR, aT, and f3R, where aR and f3R 
are the desired type I and II error rates associated with the Simon 2-Stage design, 
respectively. The value aT is the probability of stopping early if the true toxicity 
rate is less than or equal to PTo ' The specific combinations utilized in the 
simulations are reported in Table 3. The toxicity boundary values are reported in 
Table 4. The boundary values reported in Table 4 are after manual tweaking to 
achieve the desired size. It is also important to note that it is difficult to stop the 
trial very early due to the large confidence intervals. In many instances, dependent 
on the selection of the design parameters, it is not possible to stop the trial before 5 
patients are accrued. 
TABLE 3 
Values of the Combined Procedure Parameters Considered for Simulation 
Simon 2-Stage Design Parameters Toxicity Parameters 
PRo PRA aR fiR rl nl r n PTo aT 
0.30 0.50 0.05 0.10 8 24 24 63 0.33 0.025 0.050 0.100 
0.30 0.50 0.10 0.10 7 22 17 46 0.33 0.050 0.100 0.150 
0.30 0.50 0.05 0.10 8 24 24 63 0.09 0.025 0.050 0.100 
0.30 0.50 0.10 0.10 7 22 17 46 0.09 0.050 0.100 0.150 
0.20 0.35 0.05 0.10 8 37 22 83 0.33 0.025 0.050 0.100 
0.20 0.35 0.10 0.10 5 27 16 63 0.33 0.050 0.100 0.150 
0.20 0.35 0.05 0.10 8 37 22 83 0.09 0.025 0.050 0.100 
0.20 0.35 0.10 0.10 5 27 16 63 0.09 0.050 0.100 0.150 
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TABLE 4 
Toxicity Boundary Values 
PRo = 0.3, P RA = 0.5, D:R = 0.05, fJR = 0.10, P To = 0.33 
D:T # of Observations 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 
0.025 # of Toxicities . 6 7 8 9 9 10 10 11 11 11 12 12 13 13 14 14 14 15 15 16 16 17 17 18 18 
0.050 # of Toxicities ..... 5 6 7 8 8 8 9 10 10 10 11 11 12 12 12 13 13 14 14 15 15 16 16 17 17 17 
0.0101 # of Toxicities .. 778 8 9 9 9 10 11 11 11 11 12 12 13 14 14 14 15 15 15 16 16 17 
D:T # of Observations 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 4748 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 
0.025 # of Toxicities 19 19 19 20 20 21 21 22 22 23 23 23 24 24 25 25 26 26 25 27 28 28 28 28 29 29 30 31 31 31 31 32 
~ 0.050 # of Toxicities 18 18 19 19 20 20 20 21 21 22 22 23 23 23 24 24 25 25 25 26 26 27 27 28 28 28 29 29 30 30 31 31 
0.100 # of Toxicities 17 18 18 18 19 19 20 20 20 21 21 22 22 23 23 23 24 24 24 25 25 26 26 26 27 27 28 28 28 29 29 30 
PRo = 0.3, P RA = 0.5, D:R = 0.10, fJR = 0.10, PTo = 0.33 
D:T # of Observations 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 
0.050 # of Toxicities . 5 6 7 7 8 9 9 9 10 10 11 11 12 12 12 13 14 14 
0.100 # of Toxicities ..... 5 6 7 7 8 8 9 9 9 9 10 11 11 11 12 13 13 13 
0.1501 # of Toxicities . 5 5 6 6 7 7 8 8 9 9 10 10 10 11 11 12 12 13 
D:T # of Observations 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 
0.050 # of Toxicities 14 15 16 16 16 16 17 17 18 18 19 19 19 20 20 21 22 22 22 23 23 24 24 
0.100 # of Toxicities 13 14 14 15 15 16 16 16 17 17 18 18 19 19 20 20 20 21 21 21 22 22 23 
0.150 # of Toxicities 13 13 14 14 15 15 16 16 16 17 17 18 18 18 19 20 20 20 21 21 21 22 22 
tV 
O"l 
P1V:J = 0.3, PRA = 0.5, exR = 0.05, (3R = 0.10, PTo = 0.09 
exT # of Observations 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 
0.025 # of Toxicities .. 5 5 6 6 6 6 6 6 6 6 6 6 7 7 7 7 7 7 7 7 7 8 8 7 8 
0.050 # of Toxicities . 4 4 4 4 4 4 4 4 5 5 5 5 5 6 6 6 6 6 6 7 7 7 7 7 7 7 
0.100 # of Toxicities 3 3 3 3 344 4 4 4 4 5 5 5 5 5 5 6 5 6 6 6 6 6 7 7 7 
exT # of Observations 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 
0.025 # of Toxicities 8 8 8 8 8 9 9 9 9 9 10 10 10 10 10 10 11 11 11 11 11 11 11 11 11 12 12 12 12 12 12 12 13 
0.050 # of Toxicities 8 8 8 8 8 8 8 9 9 9 9 9 9 9 10 10 10 10 10 10 10 11 11 11 11 11 11 11 12 12 12 12 12 
0.100 # of Toxicities 7 7 7 7 8 8 8 8 8 8 8 8 9 9 9 9 9 9 9 10 10 10 10 10 10 10 10 11 11 11 11 11 11 
P1V:J = 0.3, PRA = 0.5, exR = 0.10, (3R = 0.10, PTo = 0.09 
exT # of Observations 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 
0.050 # of Toxicities .. 3 3 4 4 4 4 4 5 5 5 5 5 5 5 5 6 6 6 6 6 6 6 7 7 7 7 7 
0.100 # of Toxicities .. 3 3 3 3 4 4 4 4 4 4 4 4 4 5 5 5 5 5 5 6 6 6 6 6 6 7 7 
0.150 # of Toxicities . 2 2 3 3 3 3 3 3 3 4 4 4 4 4 4 5 5 5 5 5 5 6 6 6 6 6 6 7 
exT # of Observations 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 
0.050 # of Toxicities 7 8 8 8 8 8 8 8 8 9 9 9 9 9 9 10 
0.100 # of Toxicities 7 7 7 7 7 8 8 8 8 8 8 8 8 9 9 9 
0.150 # of Toxicities 7 7 7 7 7 7 7 8 8 8 8 8 8 8 8 8 
PRo = 0.20, PRA = 0.35, aR = 0.05, fiR = 0.10, PTo = 0.33 
aT # of Observations 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 
0.025 # of Toxicities . . . 7 7 8 9 10 10 11 11 11 12 12 13 13 14 14 15 15 15 16 17 17 17 18 
0.050 # of Toxicities ..... 5 6 7 8 8 8 9 9 10 10 11 11 12 12 13 13 14 14 15 15 17 16 16 17 17 
0.1001 # of Toxicities . . 6 7 7 8 8 8 9 9 10 11 11 11 12 12 13 13 14 14 15 15 15 15 16 16 
aT # of Observations 31 32 33 34 35 36 37 38 3940 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 
0.025 # of Toxicities 18 19 19 20 20 20 21 22 22 22 23 23 23 24 24 25 25 26 26 26 27 27 28 28 29 29 29 30 30 31 
0.050 # of Toxicities 17 18 18 19 19 20 21 21 21 21 22 22 23 23 23 24 24 25 25 26 26 26 27 27 28 28 29 29 30 30 
0.100 # of Toxicities 17 17 18 18 18 19 19 20 20 20 21 21 22 22 23 23 23 24 24 25 25 25 26 26 27 27 27 28 28 29 
aT # of Observations 61 62 63 64 65 66 6768 69 70 71 72 73 74 75 76 7778 79 80 81 82 83 
0.025 # of Toxicities 31 32 32 32 33 33 34 34 34 35 35 36 36 36 37 37 38 38 39 39 39 40 40 
!:::5 0.050 # of Toxicities 30 31 31 31 32 32 33 33 34 34 34 35 35 35 36 36 37 37 37 38 38 39 39 
0.100 # of Toxicities 29 29 30 30 31 31 31 32 32 33 33 33 34 34 35 35 35 36 36 37 37 37 38 
tv 
00 
PRo = 0.20, PRA = 0.35, aR = 0.10, PR = 0.10, PTo = 0.33 
aT # of Observations 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 
0.050 # of Toxicities . 5 6 7 8 8 8 9 10 10 10 11 11 12 12 12 13 13 14 14 15 15 16 16 17 17 
0.100 # of Toxicities ... 7 7 7 8 9 9 9 10 10 11 11 11 12 12 13 14 14 14 15 15 15 16 16 
0.150 # of Toxicities 4 5 5 6 6 7 7 8 8 9 9 10 10 10 11 11 12 12 13 13 14 14 14 15 15 16 
aT # of Observations 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 
0.050 # of Toxicities 17 18 18 19 19 20 20 20 21 21 22 22 23 23 23 24 24 25 25 25 26 26 27 27 28 28 28 29 29 30 30 31 31 
0.100 # of Toxicities 17 17 18 18 18 19 19 20 20 20 21 21 22 22 23 23 23 24 24 24 25 25 26 26 26 27 27 28 28 28 29 29 30 
0.150 # of Toxicities 16 16 17 17 18 18 19 19 19 20 20 21 21 21 22 22 23 23 23 24 24 25 25 25 26 26 27 27 27 28 28 28 29 
PRo = 0.2, PRA = 0.35, aR = 0.05, fiR = 0.10, PTo = 0.09 
aT # of Observations 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 
0.025 # of Toxicities .. 444 5 5 5 5 5 5 6 6 6 6 6 6 7 7 7 7 7 7 8 8 8 8 8 
0.050 # of Toxicities .. 4 5 5 5 5 5 5 5 5 5 5 5 5 5 6 6 6 6 6 6 7 7 7 7 7 7 
0.100 # of Toxicities 2 2 2 3 3 3 3 3 4 4 4 4 5 5 5 5 5 5 5 6 6 6 6 6 6 6 7 7 
aT # of Observations 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 
0.025 # of Toxicities 8 8 8 9 9 9 9 9 9 10 10 10 10 10 10 10 11 11 11 11 11 11 12 12 12 12 12 12 12 13 
0.050 # of Toxicities 8 8 8 8 8 8 8 8 9 9 9 9 9 10 10 10 10 10 10 10 11 11 11 11 11 11 11 11 12 12 
0.100 # of Toxicities 7 7 7 7 7 8 8 8 8 8 8 8 9 9 9 9 9 9 9 10 10 10 10 10 10 10 11 11 11 11 
aT # of Observations 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 
0.025 # of Toxicities 13 13 13 13 13 13 13 13 14 14 14 14 14 14 14 15 15 15 15 15 15 15 15 
~ 0.050 # of Toxicities 12 12 12 12 12 13 13 13 13 13 13 13 14 14 14 14 14 14 14 14 15 15 15 
0.100 # of Toxicities 11 11 11 11 12 12 12 12 12 12 12 12 13 13 13 13 13 13 13 14 14 14 14 
C;.;l 
o 
PRo = 0.20, P RA = 0.35, aR = 0.10, (3R = 0.10, PTo = 0.09 
aT # of Observations 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 
0.050 # of Toxicities .. 44444 4 4 4 5 5 5 5 5 6 6 6 6 6 6 777 7 7 7 7 
0.100 # of Toxicities .333334 4 4 4 4 4 5 5 5 5 5 5 6 5 6 6 6 6 6 777 
0.150 # of Toxicities .3333333344444455555 5 6 6 6 6 6 6 6 
aT # of Observations 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 
0.050 # of Toxicities 8 8 8 8 8 8 8 9 9 9 9 9 9 9 10 10 10 10 10 10 10 11 11 11 11 11 11 11 12 12 12 12 12 
0.100 # of Toxicities 7 7 7 7 8 8 8 8 8 8 8 8 9 9 9 9 9 9 9 10 10 10 10 10 10 10 10 11 11 11 11 11 11 
0.150 # of Toxicities 7 7 7 7 7 7 7 7 8 8 8 8 8 8 8 9 9 9 9 9 9 9 9 9 10 10 10 10 10 10 11 11 11 
3.6 Simulation Procedure 
The size and power of the various combinations are evaluated in similar 
manners. The basic concept is described in the following steps which are repeated 
100,000 times for each data point displayed in the following graphics. 
The simulation is conducted in five basic steps. 
• Generate n observations from a correlated bivariate binomial distribution with 
marginal probabilities PR = P(XRk = 1) and PT = P(XTk = 1). 
• Sequentially monitor the toxicity for subjects 1 to (nl - 1). If the cumulative 
number of toxicities is equal to or exceeds the corresponding boundary, then 
we stop the trial and accept the null hypothesis. 
• If the trial did not terminate, then at observation nl sum up the total number 
of responses. If there are rl or fewer responses, then we halt the trial. If there 
are more than rl responses, then compare the number of toxicities through 
patient nl to the associated boundary bn1 . If it is equal to or exceeds the 
boundary, then discontinue the study. 
• If the trial did not stop, then sequentially monitor the toxicity associated with 
observations (nl + 1) to (n - 1). If the number of toxicities is equal to or 
exceeds any of the associated boundaries for the corresponding number of 
subjects, then stop the trial. 
• Finally, at observation n, we do not reject the null hypothesis if there are r or 
fewer responses or if the number of toxicities exceeds bn . 
The simulated type I error rate is calculated for each combination of PRo, 
PRA , PTo' aR, aT, (3R reported in Table 5 and m· P(XRk = 1, X Tk = 1) = m· Pll 
where m E {O, 0.01, 0.02, ... ,0.98,0.99, l.00}. The sequence resulting from the 
product of m and Pll produces the smooth figures discussed in future paragraphs. 
The power analysis is performed in a two step process. The first step is to 
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determine all combinations of probabilities associated with response and toxicity. 
This is completed by creating two sequences from 0 to 1 by 0.01 increments. Then 
all possible combinations of the two sequences are determined, which allows the 
complete power surface to be specified. The power surface is determined under the 
assumption that toxicity and response are independent. Finally, the effect of the 
joint probability on the power is analyzed. In order to limit the number of 
possibilities, the response rate is fixed at the alternative value, PRA , specified in the 
Simon 2-Stage design. Then the largest toxicity rate which maintains approximately 
90% power in the combined procedure is selected. If it is not possible to obtain 90% 
power, then the largest toxicity rate that achieves the largest power is selected. 
3.7 Simulation Results - Nominal Size 
Figure 2 graphically displays the alpha-level of the combined procedure when 
PRo = 0.3, PRA = 0.5, aR = 0.05, (3R = 0.1, PTa = 0.33 and aT E {0.025, 0.05, 0.10}. 
We can see that in each case the size of the resulting test does not exceed the 
alpha-level specified for efficacy in the Simon 2-Stage design. The nominal size of 
the bivariate design decreases as the probability of experiencing both events at the 
same time increases. Larger values of aT result in a design that becomes more 
conservative as the probability of a person experiencing both a response and toxicity 
increases. 
Another important observation is the effect of sample size on the nominal size 
of the combined procedure. Figure 3 displays the type I error rate when PRo = 0.3, 
P RA = 0.5, aR = 0.10, (3R = 0.10, PTa = 0.33 and aT E {0.05, 0.10, 0.15}. The total 
sample size is 46, which is less than 63 in the previous example. We can see that the 
nominal size displays the same characteristics except that it does not obtain the 
desired value when the probability of experiencing both events is O. The simulation 
was designed to include Simon 2-Stage design parameters that would result in 
various sample sizes. A larger total sample size is required when PRo = 0.2, 




























0 0 Empirical 
N 
- Theoretical 0 
ci 
0.00 0.10 0.20 0.30 0.00 0.10 0.20 0.30 0.00 0.10 0.20 0.30 
Figure 2. Type I Error of Combined Procedure with PRo = 0.3, P RA = 0.5, aR = 0.05, 
and PTo = 0.33 
desired alpha-level is almost achieved when the joint probability is O. Again, larger 
values of aT result in a bivariate design that becomes more conservative as the joint 
probability increases. 
3.8 Simulation Results - Power 
The surface in Figure 4 is the power surface for all possible combinations of 
P RA and PTA when the design parameters are PRo = 0.3, P To = 0.33, aT = 0.05, 
aR = 0.05, and (3R = 0.1. The surface implies that the procedure successfully 
identifies agents with a high response rate and low toxicity rate. Figure 5 displays a 
slice of the power curve over the various toxicity rates when the response rate is 
fixed at PRA = 0.5. The figure displays the three different curves associated with the 
different choices of aT evaluated in the simulation. We can see that smaller values 
of aT result in a slightly more powerful combined procedure. The same is true when 
the alpha-level associated with the Simon 2-Stage design is increased to 0.10 which 
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P11 
Figure 3. Type I Error of Combined Procedure with PRo = 0.3, P RA = 0.5, O'.R = 0.10, 
and PTo = 0.33 
is depicted in Figure 6. 
Finally, we examine the effect of the joint probability of a response and 
toxicity occurring at the same time on the power. In order to examine the effect, we 
fix the response rate at the alternative value specified in the Simon 2-Stage design. 
The toxicity rate was selected from the simulated results so the combined 
procedure's power is close to 0.90. The exact value of 0.90 is not possible to find 
since we are using simulated results and the underlying distribution is discrete. It is 
also important to note that the combined procedure may not achieve the power 
specified in the Simon 2-Stage design. In Figure 6, we see that the maximum power 
achieved is only 88%. In Figures 7 and 8, we also see that the power declines slightly 
as the joint probability of experiencing both a response and toxic event increases. 
The remaining simulations produce very similar results so they are not 
included in the discussion. Table 5 contains a summary of the simulation results 
associated with the nominal size. It is important to note that the combined 




















Figure 4. Power Surface of Combined Procedure Over Toxicity Rate with PRo = 0.3, 
D:R = 0.05 and D:T = 0.05 
distribution. Also, the solid lines in Figures 2, 3, 7, and 8 are graphic representation 
of the theoretical formulas describing the characteristics of the combined procedure. 
3.9 Discussion 
The combined procedure is a novel way to include toxicity considerations into 
a phase II trial designed with the Simon 2-Stage methodology. The result is a trial 
that incorporates two endpoints simultaneously that does not inflate the type I 
error rate specified for the response. The boundaries associated with the toxic 
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Toxicity Rates 
Figure 5. Power Curve of Combined Procedure Over Toxicity Rate with PRo = 0.3, 
PRA = 0.5, and O'.R = 0.05 
continuous toxicity monitoring methodology requires specification of the maximum 
tolerated toxicity rate, the probability of stopping the trial early if the toxicity rate 
is in the null, and the total sample size returned by Simon's procedure. 
The simulations indicate that the combination design maintains many of the 
properties of the Simon 2-Stage design. The overall type I error rate does not 
exceed the value associated with the response. In fact, the procedure becomes more 
conservative as the probability of experiencing both a toxicity and a response 
increases. The sample size may adversely affect both the size and the power of the 
combined procedure. The desired alpha-level may not be maintained when the joint 
probability is 0 for small sample sizes. A sample size that is too small may also 
result in a less powerful combined procedure than desired. Interestingly, the joint 
probability of experiencing both events at the same time has very little impact on 
the power, as displayed in figured 7 and 8. 
Although the combined procedure has some nice properties, there are some 
limitations that may reduce its utility. The first limitation is associate patient 
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Toxicity Rates 
Figure 6. Power Curve of Combined Procedure Over Toxicity Rate with PRo = 0.3, 
PRA = 0.5, and CtR = 0.10 
This implies that the trial is beneficial for agents which may cause severe toxicities 
very quickly. The second limitation is associated with the way the trial is designed. 
The alternative value is specified for the response but not the toxicity rate. The 
theoretical expressions, or the simulations, can be utilized to determine the value of 
the toxicity rate the combined procedure has power to detect, given the alternative 
value associated with the response. In conclusion, the combined procedure is a 
viable choice in specific situations since it maintains some of the properties 
associated with the Simon 2-Stage design. The combined procedure is a feasible way 
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Figure 7. Effect of Joint Probability on Power Curve PRo = 0.3, P RA = 0.5, D:R = 0.05, 
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Figure 8. Effect of Joint Probability on Power Curve PRo = 0.3, P RA = 0.5, D:R = 0.10, 




Empirical Size of the Combined Procedure Based on 100,000 Simulations 
P(XRk = 1 and XTk = 1) = 
PRo PRA aR (3R PTo aT 0 PR,PT min(PR, PT) Actual aR 
0.30 0.50 0.05 0.10 0.33 0.025 0.0495 0.0493 0.0380 0.0497 
0.30 0.50 0.05 0.10 0.33 0.050 0.0493 0.0481 0.0304 0.0497 
0.30 0.50 0.05 0.10 0.33 0.100 0.0486 0.0456 0.0196 0.0497 
0.30 0.50 0.10 0.10 0.33 0.050 0.0590 0.0565 0.0384 0.0974 
0.30 0.50 0.10 0.10 0.33 0.100 0.0583 0.0534 0.0251 0.0974 
0.30 0.50 0.10 0.10 0.33 0.150 0.0573 0.0504 0.0169 0.0974 
0.30 0.50 0.05 0.10 0.09 0.025 0.0491 0.0473 0.0440 0.0497 
0.30 0.50 0.05 0.10 0.09 0.050 0.0486 0.0461 0.0408 0.0497 
0.30 0.50 0.05 0.10 0.09 0.100 0.0473 0.0437 0.0343 0.0497 
0.30 0.50 0.10 0.10 0.09 0.050 0.0588 0.0567 0.0480 0.0974 
0.30 0.50 0.10 0.10 0.09 0.100 0.0573 0.0537 0.0413 0.0974 
0.30 0.50 0.10 0.10 0.09 0.150 0.0552 0.0505 0.0357 0.0974 
0.20 0.35 0.05 0.10 0.33 0.025 0.0474 0.0476 0.0404 0.0487 
0.20 0.35 0.05 0.10 0.33 0.050 0.0468 0.0464 0.0356 0.0487 
0.20 0.35 0.05 0.10 0.33 0.100 0.0460 0.0440 0.0284 0.0487 
0.20 0.35 0.10 0.10 0.33 0.050 0.0986 0.0963 0.0801 0.0999 
0.20 0.35 0.10 0.10 0.33 0.100 0.0962 0.0913 0.0667 0.0999 
0.20 0.35 0.10 0.10 0.33 0.150 0.0941 0.0862 0.0555 0.0999 
0.20 0.35 0.05 0.10 0.09 0.025 0.0485 0.0483 0.0400 0.0487 
0.20 0.35 0.05 0.10 0.09 0.050 0.0479 0.0471 0.0352 0.0487 
0.20 0.35 0.05 0.10 0.09 0.100 0.0463 0.0441 0.0285 0.0487 
0.20 0.35 0.10 0.10 0.09 0.050 0.0981 0.0964 0.0789 0.0999 
0.20 0.35 0.10 0.10 0.09 0.100 0.0947 0.0915 0.0656 0.0999 
0.20 0.35 0.10 0.10 0.09 0.150 0.0911 0.0865 0.0560 0.0999 
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CHAPTER 4 
FORMALZIED PHASE II BIVARIATE MULTISTAGE 
DESIGN 
The phase II clinical trial is usually designed to test the efficacious attributes 
of an agent that passed through a phase I study. The trials are often single-arm 
studies designed to test the clinical response rate against some pre-specified value, 
which represents the maximum response rate that is not clinically interesting 
(Stallard et al., 2001). The clinical response rate (referred to as response rate) can 
consist of complete response (CR), partial response (PR), stable disease (SD), or 
progressive disease (PD). Typically, the studies are designed to measure some 
combination of the different response rates, such as objective response (OR = CR + 
PR) or sustained response (SR = CR + PR + SD) (FDA, 2007). The designs can 
incorporate multiple stages or interim analysis. Green (2006) notes that most phase 
II trials incorporate two stages with the Simon 2-Stage design (Simon, 1989) being 
the most popular. 
The trials must also incorporate patient safety. In fact, the data monitoring 
committee is responsible for the protection of the trial participants from harm due 
to the treatment under study (Demets et al., 2005). The maximum tolerated dose 
may not be clearly defined by the small phase I study, and thus might lead to more 
toxic events than desired (Tournoux et al., 2007). There are formal two-stage 
designs that incorporate both response and toxicity. Typically, grade 3 and above 
toxic events are monitored where the Common Toxicity Criteria (NCI, 2009) is used 
to assess the level of toxicity. The earliest such designs include both frequentist and 
Bayesian philosophies. The first frequentist based designs, which include both 
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response and toxicity, were proposed by Conaway and Petroni (1995), as well as 
Bryant and Day (1995). Both designs rely on exact calculations and maintain the 
small sample sizes expected in phase II trials. The concept was recently expanded 
by Jin (Jin, 2007) to allow for tradeoffs between toxicity and response to be 
included in the trial design. Thall, Simon, and Estey (Thall et aI., 1996) provide a 
Bayesian design that sequentially monitors safety and efficacy at the same time. 
Often, the univariate response statistic is augmented with an ad hoc toxicity 
stopping rule. The toxicity monitoring assists the data monitoring committee with 
the decision to continue the study while protecting the trial participants. The ad 
hoc stopping rules typically examine the data once during the trial. Ivanova et al. 
(2005) provide an example of a stopping rule for safety that is included in an ad hoc 
manner. The trial will stop early if 13 or more of the first 20 patients enrolled into 
an arm experienced toxicity. In some instances, this may not provide enough 
guidance. So, they propose a toxicity monitoring schedule that examines the 
number of toxicities after each subject is enrolled in the trial. Ray and Rai (2011a) 
combine the continuous toxicity monitoring with the Simon 2-Stage design (Simon, 
1989). They discover theoretical expressions that accurately reflect the operating 
characteristics of the combined procedure. They also note that the continuous 
toxicity monitoring may be too aggressive in some instances since the trial will need 
to stop after each patient is treated. 
In this chapter, we propose a toxicity monitoring schedule that is combined 
with a multistage design for response. The toxicity monitoring can be performed on 
groups of patients. This procedure can also be applied more frequently than the 
evaluation for response. For instance, the toxicity monitoring can be performed four 
times, while the response evaluation is performed only twice. The safety 
examination can correspond with the number and time of the data monitoring 
committee's meetings, so they have statistical guidance for the decisions required of 
them. The design includes both endpoints of interest, leverages exact calculations, 
and maintains the expected sample sizes in phase II trials. 
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4.1 Historical Designs 
The clinical trial design evaluates both response and toxicity simultaneously. 
The specific hypotheses the design evaluates are 
Ho : PR ::; PRv or PT 2: PTo 
versus (14) 
where PRo is maximum response that is not clinically interesting, PRA is the 
minimum response rate that is clinically interesting, PTo is the maximum tolerated 
toxicity rate, and PTA is the minimum toxicity that is unacceptable. 
In order to find the sample size we also need to specify the global type I error 
rate, 0:, as well as the type II error rate, (3. We also need O:T which is the probability 
of declaring a non-toxic treatment toxic based solely on the marginal count of the 
toxic events. In terms of our hypothesis, the type I error is declaring a new agent 
sufficiently promising when the response rate is too low, the toxicity rate is too 
high, or both. The type II error is the probability of rejecting a sufficiently 
promising agent. 
Suppose that both response and toxic events are binary outcomes of a 
single-arm phase II trial. Let Xrti be the observation of the ith person with response 
r and toxicity t (r, t = 0, 1). Then Xrti = (XOOi' XOli , XlOi , X lli ) follows a 
multinomial distribution with parameters POO, POl, PlO , and Pll. A response for the 
ith person is X Ri = XlOi + Xlli and a toxic event is X Ti = X01i + X lli . The 
probability of a response is PR = PlO + Pll and the probability of a toxicity is 
PT = POl + Pu. The data layout for the ith person is displayed in Table 6. Let 
Yrtm = L:~l Xrti be the accumulated data up to and including the mth observation 
for r = 0,1 and t = 0, 1. The total number of responses will be defined as 
YRm = L:~l L:;=o X lti = L:~l X Ri and the total number of toxicities will be 
YTm = L:~l L:~=o X r1i = L:~l X Ti · 
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TABLE 6 
Contingency Table for Response and Toxicity of the ith individual 
Toxicity 
No Yes 
Response No X OOi XOli 
Yes X lOi X lli X Ri 
The underlying theory assumes that the four possible responses follow a 
multinomial distribution. Aitken and Gonin (1935) provide the details that relate 
PT and PR through the correlation 
Pll - PRPT 
P = -Jr:'P::=R:;=::( 1=-=P:::=R7") p:::=T7( 1:==-=P:::::T=;::) 
where PR and PT could fall in either the null or alternative regions. We can see that 
P is an increasing function of the joint probability Pll , and that it will not take on 
all possible values in [-1,1]. The effect of the choice of p will be examined in the 
simulations. 
The Conaway and Petroni bivariate test procedure is designed to evaluate 
both response and toxicity at the same times. Let YTnk be the total number of 
toxicities experienced in the first nk subjects and YRnk be the corresponding number 
of responses in the first nk patients, for k in {1, ... , K - 1}. The total number of 
responses and toxicities through all n subjects are denoted by YRn and YTn , 
respectively. Let the critical region be denoted as 
where T I , T2 , ... , TK - I , T is the toxicity boundaries used at each evaluation and R I , 
R2 , ... , RK - I , R is the set of response boundaries assuming K stages. Then they 
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design the trial while controlling the following error rates 
Ray and Rai (2011a) considered the situation in which the toxicity is 
measured after each individual but the response is monitored based on a Simon 
2-Stage schedule. First, design the trial for the efficacious endpoint based on the 
Simon 2-Stage design. Then the toxicity boundaries are constructed using group 
sequential theory which requires the minimum toxicity rate considered unacceptable, 
the total sample size, and probability of stopping early given a safe treatment, aT. 
The corresponding continuation region, CR, is different and defined to be 
Then the trial is designed with the following constraints 
P{YRn1 > R l , YRn > RIPRo } < aR 
P{YRn1 > Rl, YRn > RIPRA } > 1- {3R 
n 
LaTi < aT 
i=l 
where the toxicity boundary values are determined as 
P{YTl ~ TIIPTO} 
P{YT2 ~ T2, YTl < TIIPTO } 
P{YTn ~ T, YTl < TI , YT2 < T2, ... , YT(n-l) < Tn-I, IPTO} 
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The values CtR and (3R are required to construct to the Simon 2-Stage design. The value CtT is the 
type I error rate associated with the toxicity monitoring. The investigation of the design led to 
theoretical expressions that can accommodate the evaluation of two different endpoints on two 
different schedules. Now, utilizing the theoretical expressions we construct a bivariate test which 
also incorporates the joint probability of both events in order to control the type I and type II 
error rates associated with the bivariate hypothesis. 
4.2 New Design 
Let K be the planned number of toxicity evaluations and L be the planned number of 
response evaluations with K f L. The continuation region is defined to be 
YTnk < Tk, k E {I, 2, ... (K - I)}, 
TRnl >Rt,lE{I,2, ... ,(L-l)}, k=l*,nk=nt, 
YTn < T, YRn > R}. 
The trial is constructed with the following constraints 
YRn" YRn2 ,···, YRnL_" YRn) E CRRRI(PRA,PTA),p} 2: 1- (3 
K 
2: CtTk ::; CtT 
k=l 
where the toxicity boundary values are determined as 
P{YTl 2: T1IPTO } 
P{YT2 2: T2, YTl < T1IPTO} 
For each n, the toxicity boundaries are fixed with the usual group sequential theory. Then 
the boundaries and interim group sizes associated with response evaluation are searched for. The 
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process is repeated over a range of sample sizes. This is an extremely flexible design which can 
include the two-stage bivariate design similar to the Conaway and Petroni methodology, as well as 
the continuous toxicity monitoring. 
We propose to search for the response boundaries and total sample size, n, given the 
pre-specified 0, (3, PRo, PRa, PTa, and PTa along with the toxicity boundaries based on OT and p. 
In other words, for possible sample sizes we can fix the toxicity boundaries, then search for the 
response boundaries that maintain the specified 0 and (3. The design with the desired 
characteristics is selected from the collection of possible designs. The design which minimizes the 
expected or the total sample size can be selected but designs with other characteristics can be 
selected as well. 
4.3 Design Based on Data Monitoring Committee's Meeting Schedule 
There are many possible designs to consider, such as a bivariate design that monitors 
response and toxicity in two stages at the same time. It is also possible to construct the continuous 
toxicity monitoring design, which monitors response in two stages. We will focus on a design that 
monitors toxicity four times and response twice, at the second and forth toxicity monitoring. The 
toxicity monitoring is equally spaced. In reality, this will correspond to a data monitoring 
committee's meeting schedule but the response is measured after several cycles of treatment in two 
stages. Since there are only four toxicity evaluations, the first response evaluation will be denoted 
as YRn2 to indicate that it includes all n2 subjects. 
The critical region is 
The constraints are 




where T1 , T2, T3 , and T are the toxicities boundaries based on the usual group sequential 
theory. The toxicity boundary values are found through a search algorithm of possible boundary 
values. The starting point is the discrete transformation of the boundary values created by the 
Pocock procedure. The Pocock procedure returns values {al' a2, a3, a4} that are associated with 
the standardized test statistics {Zl' Z2, Z3, Z4}' The transformed boundary values will be 
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denoted as {b1, b2, b3 , b4 } but the alpha-level maybe larger than specified. The following formula 
was used to modify the standardized boundary values 
(15) 
Then all possible values between 1 to (bk + 10) for k = 1,2,3,4 were calculated and all 
combinations created with b1 :S b2 :S b3 :S b4 . The set of boundary values with the smallest squared 
difference from the specified alpha-level was selected and denoted as {Tl' T2 , T3 , T} . 
Once the toxicity boundary values are determined, a search can be performed for the 
response boundaries. In a manner similar to Simon's 2-Stage design, we can find boundary values 
that either minimize the total sample size or the expected sample size. There are many designs 
available in Table 7 with different combinations of input parameters. 
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TABLE 7 
Phase II Design That Monitors Toxicity Four Times and Response at the Second and 
Forth Time 
Criteria Optimal Design Characteristics 
PTo PTA PRo PRa Tl T2 T3 T R2 n2 R N PET ASN Power 
f3 = 0.1, a = 0.05, aT = 0.05 
0.33 0.30 0.1 0.3 7 11 16 26 2 20 7 40 0.693 27.0 0.901 
0.33 0.30 0.2 0.4 9 19 19 24 5 26 15 52 0.592 36.6 0.909 
0.33 0.30 0.3 0.5 12 18 24 28 11 32 25 64 0.775 39.2 0.901 
0.33 0.30 0.4 0.6 14 19 23 32 15 34 34 68 0.762 42.3 0.901 
0.33 0.30 0.5 0.7 9 19 19 24 17 26 36 52 0.782 31.6 0.901 
0.33 0.25 0.1 0.3 7 13 20 22 3 22 7 44 0.835 25.2 0.914 
0.33 0.25 0.2 0.4 9 19 19 24 6 26 15 52 0.756 32.3 0.902 
0.33 0.25 0.3 0.5 10 16 25 25 9 28 22 56 0.686 36.8 0.907 
0.33 0.25 0.4 0.6 10 16 25 25 11 28 28 56 0.555 40.4 0.909 
0.33 0.25 0.5 0.7 12 18 24 28 18 32 38 64 0.814 38.0 0.907 
0.20 0.17 0.1 0.3 7 10 12 14 3 22 7 44 0.833 25.7 0.908 
0.20 0.17 0.2 0.4 7 10 15 19 6 28 16 56 0.694 36.4 0.916 
0.20 0.17 0.3 0.5 9 12 15 21 11 32 25 64 0.783 39.0 0.903 
0.20 0.17 0.4 0.6 8 14 16 21 15 34 34 68 0.760 42.1 0.904 
0.20 0.17 0.5 0.7 9 13 15 18 16 30 36 60 0.715 38.6 0.907 
0.20 0.15 0.1 0.3 7 10 12 14 3 22 7 44 0.832 25.7 0.917 
0.20 0.15 0.2 0.4 7 12 14 16 6 26 15 52 0.753 32.4 0.900 
0.20 0.15 0.3 0.5 7 10 15 19 9 28 22 56 0.698 36.3 0.902 
0.20 0.15 0.4 0.6 7 10 15 19 11 28 28 56 0.572 39.8 0.903 
0.20 0.15 0.5 0.7 9 13 15 18 38 32 38 64 0.821 37.8 0.904 
f3 = 0.1, a = 0.10, aT = 0.05 
0.33 0.30 0.1 0.3 8 9 14 18 1 16 5 32 0.538 23.4 0.910 
0.33 0.30 0.2 0.4 7 13 20 22 4 22 12 44 0.562 31.3 0.907 
0.33 0.30 0.3 0.5 5 10 13 16 8 26 19 52 0.641 35.4 0.923 
0.33 0.30 0.4 0.6 8 13 20 23 9 24 23 48 0.598 35.6 0.910 
0.33 0.30 0.5 0.7 7 13 20 22 13 22 30 44 0.565 31.2 0.922 
0.33 0.25 0.1 0.3 8 13 20 23 2 18 10 36 0.745 22.6 0.905 
0.33 0.25 0.2 0.4 7 11 14 18 2 18 10 36 0.301 30.7 0.904 
0.33 0.25 0.3 0.5 8 13 20 23 7 24 18 48 0.581 33.9 0.924 
0.33 0.25 0.4 0.6 8 13 20 23 10 24 23 48 0.663 31.9 0.906 
0.33 0.25 0.5 0.7 9 19 19 24 14 26 30 52 0.731 32.0 0.917 
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Criteria Optimal Design Characteristics 
PTo PTA PRo PRo Tl T2 T3 T R2 n2 R N PET ASN Power 
f3 = 0.1, a = 0.10, aT = 0.05 
0.20 0.17 0.1 0.3 5 8 10 11 1 16 5 32 0.526 23.5 0.918 
0.20 0.17 0.2 0.4 8 11 11 13 3 20 11 40 0.467 31.6 0.909 
0.20 0.17 0.3 0.5 7 10 15 15 7 24 18 48 0.571 34.2 0.915 
0.20 0.17 0.4 0.6 7 12 14 16 11 26 25 52 0.680 34.3 0.903 
0.20 0.17 0.5 0.7 7 12 14 16 14 26 30 52 0.727 33.0 0.907 
0.20 0.15 0.1 0.3 8 8 11 12 2 18 6 36 0.739 22.7 0.904 
0.20 0.15 0.2 0.4 8 8 11 12 2 18 10 36 0.287 30.9 0.902 
0.20 0.15 0.3 0.5 7 10 15 15 7 24 18 48 0.571 34.2 0.924 
0.20 0.15 0.4 0.6 7 10 15 15 10 24 23 48 0.657 32.2 0.905 
0.20 0.15 0.5 0.7 7 12 14 16 14 26 30 52 0.727 33.0 0.915 
f3 = 0.2, a = 0.05, aT = 0.05 
0.33 0.30 0.1 0.3 8 9 14 18 2 16 6 32 0.800 19.2 0.816 
0.33 0.30 0.2 0.4 7 13 20 22 6 22 12 44 0.873 24.4 0.805 
0.33 0.30 0.3 0.5 7 13 20 22 7 22 18 44 0.685 28.5 0.810 
0.33 0.30 0.4 0.6 8 13 20 23 11 24 24 48 0.795 28.7 0.817 
0.33 0.30 0.5 0.7 7 11 14 18 11 18 26 36 0.641 24.5 0.803 
0.33 0.25 0.1 0.3 8 9 14 18 2 16 6 32 0.800 19.2 0.832 
0.33 0.25 0.2 0.4 7 11 14 18 4 18 11 36 0.728 22.8 0.800 
0.33 0.25 0.3 0.5 8 13 20 23 9 24 19 48 0.853 27.3 0.806 
0.33 0.25 0.4 0.6 8 13 20 23 11 24 24 48 0.795 28.7 0.832 
0.33 0.25 0.5 0.7 7 13 20 23 12 22 27 44 0.749 27.1 0.818 
0.20 0.17 0.1 0.3 5 8 10 11 2 16 6 32 0.794 19.2 0.823 
0.20 0.17 0.2 0.4 7 10 12 14 6 22 12 44 0.870 24.9 0.814 
0.20 0.17 0.3 0.5 7 10 12 14 7 22 18 44 0.679 29.1 0.820 
0.20 0.17 0.4 0.6 7 10 15 15 11 24 24 48 0.790 29.0 0.824 
0.20 0.17 0.5 0.7 7 10 12 14 12 22 27 44 0.745 27.6 0.813 
0.20 0.15 0.1 0.3 5 8 10 11 2 16 6 32 0.794 19.2 0.831 
0.20 0.15 0.2 0.4 8 11 11 13 5 20 12 40 0.809 23.7 0.806 
0.20 0.15 0.3 0.5 7 10 15 15 9 24 19 48 0.850 27.6 0.806 
0.20 0.15 0.4 0.6 7 10 15 15 11 24 24 48 0.790 29.0 0.832 
0.20 0.15 0.5 0.7 7 10 15 15 14 24 29 48 0.849 27.6 0.805 
49 
Criteria Optimal Design Characteristics 
PTo PTA PRo PRa Tl T2 T3 T R2 n2 R N PET ASN Power 
(3 = 0.2, Q = 0.10, QT = 0.05 
0.33 0.30 0.1 0.3 5 10 13 16 2 14 4 28 0.849 15.8 0.802 
0.33 0.30 0.2 0.4 5 10 13 16 2 14 8 28 0.474 21.1 0.814 
0.33 0.30 0.3 0.5 5 10 13 16 2 14 11 28 0.200 24.9 0.801 
0.33 0.30 0.4 0.6 7 11 16 26 9 20 19 40 0.768 24.5 0.822 
0.33 0.30 0.5 0.7 8 9 14 18 10 16 22 32 0.687 2l.0 0.846 
0.33 0.25 0.1 0.3 5 10 13 16 2 14 4 28 0.849 15.8 0.817 
0.33 0.25 0.2 0.4 6 9 10 13 1 12 7 24 0.305 20.5 0.800 
0.33 0.25 0.3 0.5 5 10 13 16 3 14 11 28 0.385 22.3 0.811 
0.33 0.25 0.4 0.6 8 9 14 18 6 16 16 32 0.362 26.2 0.813 
0.33 0.25 0.5 0.7 8 9 14 18 8 16 19 32 0.618 22.1 0.834 
0.20 0.17 0.1 0.3 4 8 8 9 1 12 4 24 0.669 15.9 0.830 
0.20 0.17 0.2 0.4 6 6 11 11 2 14 8 28 0.472 2l.4 0.821 
0.20 0.17 0.3 0.5 6 6 11 11 3 14 11 28 0.383 22.6 0.804 
0.20 0.17 0.4 0.6 5 8 10 11 6 16 16 32 0.538 23.3 0.805 
0.20 0.17 0.5 0.7 5 8 10 11 8 16 19 32 0.607 22.2 0.825 
0.20 0.15 0.1 0.3 4 8 8 9 1 12 4 24 0.669 15.0 0.834 
0.20 0.15 0.2 0.4 6 6 11 11 2 14 8 28 0.472 2l.4 0.830 
0.20 0.15 0.3 0.5 6 6 11 11 3 14 11 28 0.383 22.6 0.812 
0.20 0.15 0.4 0.6 5 8 10 11 6 16 16 32 0.538 23.3 0.813 
0.20 0.15 0.5 0.7 5 8 10 11 8 16 19 32 0.607 22.2 0.833 
4.4 Simulations 
A series of simulations was constructed to evaluate the operating characteristics of the 
bivariate test procedure when the correlation is different than specified. Designs were selected from 
Table 7 to be evaluated through the simulation. The simulations will also be used to examine the 
accuracy of the analytic expressions. The simulation is conducted in the following manner: 
• Generate n observations from a correlated bivariate binomial distribution with marginal 
probabilities PR = P(XRk = 1) and PT = P(XTk = 1). 
• Compare the cumulative number of toxicities observed through the first nl patients to the 
toxicity boundary value T1 . If the number of toxicities is equal to or exceeds the boundary 
value, then stop the trial; otherwise, enroll the next (n2 - nl) patients. 
• If the trial did not terminate, then at observation n2 sum up the total number of responses. 
If there are R2 or fewer responses, then we halt the trial. Also, compare the number of 
toxicities through patient n2 to the associated boundary T2 . If YTn2 is equal to or exceeds 
the boundary, then discontinue the study. 
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• If the trial did not stop, then enroll the additional (n3 - n2) subjects. If the cumulative 
number of toxicities through patient n3 is greater than T3 - 1, then stop the trial; otherwise, 
enroll the remaining (n - n3) patients. 
• Finally, after all n subjects are enrolled we do not reject the null hypothesis if there are R or 
few responses or if the number of toxicities exceeds T - 1. 
The above procedure is repeated 100,000 times for each value 
m· P(XRk = 1 and XTk = 1) = m . PH where m E {O, 0.01, 0.02, ... ,0.98,0.99, 1.00}. The 
sequence of joint probabilities produces the smooth figures to be discussed. The joint probability is 
transformed into the correlation through the following relationship: 
The range of the correlation between response and toxicity is not [-1, 1] but is limited by 
joint probability PH. When PH = 0 the correlation will be the smallest at v'PR(1~::)~~(l-PT)' 
The largest value for PH = min(PR, PT ) > PR . PT and results in the largest value for 
p(XRk' X Tk ). 
The power analysis is performed in a two step process. The first step is to determine all 
combinations of probabilities associated with response and toxicity. This is completed by creating 
two sequences from 0 to 1 by 0.01 increments. Then all possible combinations of the two sequences 
are determined, which allows the complete power surface to be specified. The power surface is 
determined under the assumption that toxicity and response are independent. Finally, the effect of 
the correlation on the power is analyzed. 
4.5 Simulation Results 
The simulation results reported are based on the first row of Table 7. The nominal size of 
the bivariate procedure is pictured in Figure 9. The design minimizes the expected sample size and 
was created under the assumption of independence between toxicity and response. The assumption 
is equivalent to a correlation of O. We can see that that bivariate design becomes more 
conservative as the correlation increases from 0 to the maximum of 93.3 %. It is also important to 
note that the simulated type I error rate increases as the correlation goes from 0 to the minimum 
value but it does not exceed the pre-specified type I error rate. 
The average sample size (ASN) is pictured in Figure 10. The ASN is the largest when the 
correlation is the smallest and decreases as the correlation increases. The largest expected sample 
size is 27.1 and decreases to approximately 26.6 when the correlation between response and 
toxicity is at the maximum value. 
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Figure 9. Effect of Correlation on the Type I Error of the Bivariate Test with PRo = 
0.1, P RA = 0.3, PTo = 0.33, PTA = 0.30, a = 0.05, aT = 0.05 and f3 = 0.10 
Figure 11 graphically displays the effect of the correlation on the probability of early 
termination (PET). The PET is the smallest when the correlation is the smallest and increases as 
the correlation increases. The PET reaches its maximum value of 71 % when the correlation 
obtains its maximum value of 93.3%. 
The power of the bivariate design is pictured in Figure 12. The bivariate procedure 
successfully identifies treatments that induce a large response rate and low toxicity rate. We can 
also see that the combined bivariate procedure's nominal size is less than 5% when the response 
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Figure 10. Effect of Correlation on the Average Sample Size of the Bivariate Test 
with PRo = 0.1, P RA = 0.3, P To = 0.33, PTA = 0.30, a = 0.05, aT = 0.05 and (3 = 0.10 
The effect of the correlation on the bivariate procedure's power function is displayed in 
Figure 13. The power of the bivariate test is affected by misspecification of the correlation but we 
can see it never goes below the pre-specified level in this example. The trial is designed under the 
assumption of independence with an associated power of approximately 90.1 %. The power 
decreases to approximately 90% when the correlation achieves the maximum values. 
The ability to control the type I error rate over the entire null hypothesis region is difficult 
with the typical sample sizes expected in phase II single-arm trials. The design is able to control 
the type I and II error rates when both endpoints are either in the null hypothesis region or in the 
alternative hypothesis region. Next, we examine the type I error rate when one endpoint is in the 
rejection region while the other endpoint is in the acceptance region. There are two possible cases. 
First, we will consider a toxicity rate that is smaller than expected under the null 
hypothesis and allow the response rate to vary the over range of possible response values. In other 
words, the treatment does not produce enough toxic events to declare it unsafe and we consider 
many possible response rates. Figure 14 displays the power curve when the toxicity rate is fixed at 
PT = 0.25 and the response rate is allowed to vary between 5% and 70%. The parameters used to 
construct the specific design are PRo = 0.1 and P RA = 0.3. We can see that the design achieves the 
nominal size specified when the response rate is 10%. The power reaches 90% when the response 
rate attains 30%. This is the expected result based on the design parameters. 
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Figure 11. Effect of Correlation on the Probability of Early Termination of the 
Bivariate Test with PRo = 0.1, P RA = 0.3, P To = 0.33, PTA = 0.30, a = 0.05, 
aT = 0.05 and f3 = 0.10 
the null hypothesis and the toxicity rates vary over the set of possible values. The response rate is 
set at 30% and the power curve is over all possible toxicity rates between 5% and 70%. The curve 
is depicted in Figure 15. We can see that the curve decreases towards the nominal size as the 
toxicity rate increases beyond 33% but not as fast as desired. It is possible to declare a treatment 
effective with a larger than expected toxicity rate. This is not necessarily a bad thing and the 
consequences will be discussed in the Section 4.6. 
Now, we will compare the traditional Simon 2-Stage design to the total sample size and 
expected sample size from the proposed bivariate design. Table 8 contains the results of the 
Minimax and Optimal designs along with expected sample from the bivariate design. The greatest 
increase in the sample size between the Simon 2-Stage design and the new bivariate design is at 
most 35.7% for the set of parameters considered. The largest increase, due to the additional 
endpoint, is associated with the smaller sample sizes created when power is set at 80% and the 
type I error rate is lO %. The actual increase in the expected sample size is at the most 6.3 
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Figure 12. Power Surface of the Bivariate Test with PRo = 0.1, P RA = 0.3, PTa = 0.33, 
PTA = 0.30, a = 0.05, aT = 0.05 and j3 = 0.10 
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Figure 13. Effect of Correlation on the Power of the Bivariate Test with PRo = 0.1, 
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Figure 14. Marginal Power Curve Over the Response Rates when Toxicity is Fixed 
in the Alternative PRo = 0.1, PRA = 0.3, P To = 0.33, PTA = 0.30,0: = 0.05, O:T = 0.05 
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Figure 15. Marginal Power Curve Over the Toxicity Rates when Response is Fixed 
in the Alternative PRo = 0.1, P RA = 0.3, P To = 0.33, PTA = 0.30,0: = 0.05, O:T = 0.05 
and f3 = 0.10 
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TABLE 8 
Simon 2-Stage Optimal, Minimax, and Bivariate Design Total Samples and Average 
Sample Sizes (ASN) 
Criteria I Optimal I Minimax I Bivariate Design I 
P To PTA PRo P Ra N ASN N ASN N ASN 
(3 = 0.1, a = 0.05, aT = 0.05 
0.33 0.30 0.1 0.3 35 22.5 33 26.2 40 27.0 
0.33 0.25 0.1 0.3 35 22.5 33 26.2 44 25.2 
0.20 0.17 0.1 0.3 35 22.5 33 26.2 44 25.7 
0.20 0.15 0.1 0.3 35 22.5 33 26.2 44 25.7 
0.33 0.30 0.2 0.4 54 30.4 45 31.2 52 36.6 
0.33 0.25 0.2 0.4 54 30.4 45 31.2 52 32.3 
0.20 0.17 0.2 0.4 54 30.4 45 31.2 56 36.4 
0.20 0.15 0.2 0.4 54 30.4 45 31.2 52 32.4 
0.33 0.30 0.3 0.5 63 34.7 53 36.6 64 39.2 
0.33 0.25 0.3 0.5 63 34.7 53 36.6 56 36.8 
0.20 0.17 0.3 0.5 63 34.7 53 36.6 64 39.0 
0.20 0.15 0.3 0.5 63 34.7 53 36.6 56 36.3 
0.33 0.30 0.4 0.6 66 36.0 54 38.1 68 42.3 
0.33 0.25 0.4 0.6 66 36.0 54 38.1 56 40.4 
0.20 0.17 0.4 0.6 66 36.0 54 38.1 68 42.1 
0.20 0.15 0.4 0.6 66 36.0 54 38.1 56 39.8 
0.33 0.30 0.5 0.7 61 34.0 53 36.1 52 31.6 
0.33 0.25 0.5 0.7 61 34.0 53 36.1 64 38.0 
0.20 0.17 0.5 0.7 61 34.0 53 36.1 60 38.6 
0.20 0.15 0.5 0.7 61 34.0 53 36.1 64 37.8 
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Criteria I Optimal I Minimax I Bivariate Design I 
PTo PTA PRo P Ra N ASN N ASN N ASN 
f3 = 0.1, a = 0.10, aT = 0.05 
0.33 0.30 0.1 0.3 35 19.8 25 20.4 32 23.4 
0.33 0.25 0.1 0.3 35 19.8 25 20.4 36 22.6 
0.20 0.17 0.1 0.3 35 19.8 25 20.4 32 23.5 
0.20 0.15 0.1 0.3 35 19.8 25 20.4 36 22.7 
0.33 0.30 0.2 0.4 37 26.0 36 28.3 44 31.3 
0.33 0.25 0.2 0.4 37 26.0 36 28.3 36 30.7 
0.20 0.17 0.2 0.4 37 26.0 36 28.3 40 31.6 
0.20 0.15 0.2 0.4 37 26.0 36 28.3 36 30.9 
0.33 0.30 0.3 0.5 46 29.9 39 35.0 52 35.4 
0.33 0.25 0.3 0.5 46 29.9 39 35.0 48 33.9 
0.20 0.17 0.3 0.5 46 29.9 39 35.0 48 34.2 
0.20 0.15 0.3 0.5 46 29.9 39 35.0 48 34.2 
0.33 0.30 0.4 0.6 46 30.2 41 33.8 48 35.6 
0.33 0.25 0.4 0.6 46 30.2 41 33.8 48 31.9 
0.20 0.17 0.4 0.6 46 30.2 41 33.8 52 34.3 
0.20 0.15 0.4 0.6 46 30.2 41 33.8 48 32.2 
0.33 0.30 0.5 0.7 45 29.0 39 31.0 44 31.2 
0.33 0.25 0.5 0.7 45 29.0 39 31.0 52 32.0 
0.20 0.17 0.5 0.7 45 29.0 39 31.0 52 33.0 
0.20 0.15 0.5 0.7 45 29.0 39 31.0 52 33.0 
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Criteria I Optimal I Minimax I Bivariate Design I 
P To PTA PRo P Ra N ASN N ASN N ASN 
0.33 0.30 0.1 0.3 29 15.0 25 19.5 32 19.2 
0.33 0.25 0.1 0.3 29 15.0 25 19.5 32 19.2 
0.20 0.17 0.1 0.3 29 15.0 25 19.5 32 19.2 
0.20 0.15 0.1 0.3 29 15.0 25 19.5 32 19.2 
0.33 0.30 0.2 0.4 43 20.6 33 22.3 44 24.4 
0.33 0.25 0.2 0.4 43 20.6 33 22.3 36 22.8 
0.20 0.17 0.2 0.4 43 20.6 33 22.3 44 24.9 
0.20 0.15 0.2 0.4 43 20.6 33 22.3 40 23.7 
0.33 0.30 0.3 0.5 46 23.6 39 25.7 44 28.5 
0.33 0.25 0.3 0.5 46 23.6 39 25.7 48 27.3 
0.20 0.17 0.3 0.5 46 23.6 39 25.7 44 29.1 
0.20 0.15 0.3 0.5 46 23.6 39 25.7 48 27.6 
0.33 0.30 0.4 0.6 46 24.5 39 34.4 48 28.7 
0.33 0.25 0.4 0.6 46 24.5 39 34.4 48 28.7 
0.20 0.17 0.4 0.6 46 24.5 39 34.4 48 29.0 
0.20 0.15 0.4 0.6 46 24.5 39 34.4 48 29.0 
0.33 0.30 0.5 0.7 43 23.5 37 27.7 36 24.5 
0.33 0.25 0.5 0.7 43 23.5 37 27.7 44 27.1 
0.20 0.17 0.5 0.7 43 23.5 37 27.7 44 27.6 
0.20 0.15 0.5 0.7 43 23.5 37 27.7 48 27.6 
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Criteria I Optimal I Minimax I Bivariate Design I 
P To PTA PRo P Ra N ASN N ASN N ASN 
f3 = 0.2, a = 0.10, aT = 0.05 
0.33 0.30 0.1 0.3 18 12.7 18 12.7 28 15.8 
0.33 0.25 0.1 0.3 18 12.7 18 12.7 28 15.8 
0.20 0.17 0.1 0.3 18 12.7 18 12.7 24 15.9 
0.20 0.15 0.1 0.3 18 12.7 18 12.7 24 15.0 
0.33 0.30 0.2 0.4 25 17.7 24 19.5 28 21.1 
0.33 0.25 0.2 0.4 25 17.7 24 19.5 24 20.5 
0.20 0.17 0.2 0.4 25 17.7 24 19.5 28 21.4 
0.20 0.15 0.2 0.4 25 17.7 24 19.5 28 21.4 
0.33 0.30 0.3 0.5 32 19.7 28 20.1 28 24.9 
0.33 0.25 0.3 0.5 32 19.7 28 20.1 28 22.3 
0.20 0.17 0.3 0.5 32 19.7 28 20.1 28 22.6 
0.20 0.15 0.3 0.5 32 19.7 28 20.1 28 22.6 
0.33 0.30 0.4 0.6 38 20.7 28 21.7 40 24.5 
0.33 0.25 0.4 0.6 38 20.7 28 21.7 32 26.2 
0.20 0.17 0.4 0.6 38 20.7 28 21.7 32 23.3 
0.20 0.15 0.4 0.6 38 20.7 28 21.7 32 23.3 
0.33 0.30 0.5 0.7 32 19.7 28 21.5 32 21.0 
0.33 0.25 0.5 0.7 32 19.7 28 21.5 32 22.1 
0.20 0.17 0.5 0.7 32 19.7 28 21.5 32 22.2 
0.20 0.15 0.5 0.7 32 19.7 28 21.5 32 22.2 
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4.6 Discussion 
The design sacrifices the ability to detect toxicity rates larger than desired when the 
response rate is also large enough to reject the null hypothesis. The trial will successfully identify 
agents with ineffective response with small toxicity. The data monitoring committee must carefully 
weight the cost of the additional response in terms of toxicity. Regardless of the results of the test, 
an agent that is efficacious maybe allowed to have a larger toxicity rate to achieve the result. In 
this situation, it is imperative that the data monitoring committee understand the consequences of 
the design, including the relatively small sample sizes, and make appropriate recommendations 
that consider more than just the statistical hypothesis test. 
In the end, a trial that is very similar to the Simon 2-Stage design is possible that allows 
guidance for the data monitoring committee at each meeting. The additional cost of the guidance 
is small while the characteristics are preserved regardless of the toxicity rate. In large multiple 
center trials, the additional collection and analysis of the data maybe too burdensome, but the 
design can be modified to check both response and toxicity in two stages. The design also allows 
one to set toxicity as the priority instead of response, if the principal investigator is concerned with 
accurate monitoring of toxic events. The design can also incorporate other assumptions related to 
the correlation. The current algorithm requires a computing cluster with 25 nodes to search for the 
sample sizes. The next problems to consider include more efficient search algorithms and point 
estimation for response given the multistage, bivariate design. The flexible design also allows one 
to consider different monitoring schedules for response and toxicity. 
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CHAPTER 5 
PROPER INFERENCE AFTER SINGLE-ARM, 
MULTISTAGE, BIVARIATE CLINICAL TRIALS 
Treatments progress through phases in the drug evaluation process. The first clinical 
experiments, or phase I trials, are small studies intended to find the maximum tolerated dose 
(MTD). The MTD is typically the largest dose that is safe to administer. In the oncology setting, 
larger doses of cytotoxic agents usually result in larger response rates, but also increase the number 
of toxic events. The MTD will proceed into a phase II clinical trial designed to test the efficacy of 
the new agent against the standard treatment. The phase II trial can take on many different 
forms, but the most popular is the single-arm design (Stallard et al., 2001). If the new treatment is 
both safe and efficacious, then it will proceed into the larger phase III clinical trial. The phase III 
trial is a confirmatory study, whereas the phase II clinical trial is exploratory. 
There are several single-arm, phase II clinical trial designs that incorporate multiple 
examinations of the data, as well as multiple endpoints. Conaway and Petroni (1995), as well as 
Bryant and Day (1995), both provide two-stage frequentist based designs that incorporate response 
and toxicity simultaneously. lvanova et al. (2005) propose a phase II single-arm clinical trial design 
that measures response once at the end of the trial, but evaluates toxicity after each patient is 
enrolled. This is also referred to as continuous toxicity monitoring. Ray and Rai (2011b) expand 
the concept into a formal design that allows the toxicity to be monitored on a different schedule 
than response. The design also encompasses the continuous toxicity monitoring concept with two 
or more examinations of response. The design framework provides statistical guidance associated 
with toxicity monitoring. Further, the design allows multiple evaluations of the response rate 
during the conduct of the trial. Ray and Rai provide an example design that monitors toxicity four 
times. The design also evaluates response at the second and final toxicity examinations. 
The design of the phase III clinical trial requires an estimate of the response rate based on 
the phase II trial results. Jung and Kim (2004) provide a uniformly minimum variance unbiased 
estimate (UMVUE) of the response rate for single-arm, multiple-stage trials that only examine 
response. They note that the usual maximum likelihood estimate (MLE) is biased due to the 
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optimal sampling effect. The bias is a consequence of the trial design, since it results in only 
observing extreme values due to crossing the pre-specified boundaries. 
In this chapter, we investigate an estimator for response based on the clinical trial designs 
that include both response and toxicity. We also consider the ability to monitor the toxicity on a 
different schedule from response, which includes the continuous toxicity monitoring example. 
Section 5.1 contains the theoretical derivation of the estimator, which is explored through 
simulation in Section 5.3. 
5.1 Distribution Theory 
Analysis of the distribution of response and toxicities is required before we can determine 
expressions for an unbiased point estimator. Suppose that both response and toxic events are 
binary outcomes. Let k E {I, 2, ... K} be the number of stages in which the data will be evaluated. 
Let n1, ... nK be the number of subjects accrued at each stage in the trial such that 
n1 + ... + nK = n where n is total sample size. Let Xrtk be the number of observations associated 
with the kth stage where r indicates if a response occurred and t indicates if a toxic event occurred. 
Then Xrtk = (XOOk, X Olk , X 10k, X 1lk) follows a multinomial distribution with parameters 
POO , POI, P lO , and PH' The probability of a response is PR = P lO + PH and the probability of a 
toxicity is PT = POl + PH. Let Yrtm = 2::;;'=1 Xrtk be the accumulated data through the mth stage 
for r = 0,1 and t = 0, l. The total number of responses through stage m will be defined as 
YRm = 2::;:12::;=0 Xltk = 2::;;'=1 XRk and the total number of toxicities through stage m will be 
YTm = 2::;:~1 2::;=0 X r1k = 2::;;'=1 XTk· The response boundary values will be denoted as Rk and 
the toxicity boundary values will be denoted as n. The trial should stop if YRk ~ Rk or if 
YTk ::::: Tk, for k = 1,2, ... , K. 
where 
The full joint probability of YRm responses and YTm toxicities at stage m is 
f(m, YRm, YTmI P ) 
= Pr{M = m, YRm = YRm, YTm = YTrnIP} 
= Pr{YRm = YRm, YTm = YTm, YRk ::::: Rk + 1, YTk ~ n - 1, k = 1··· (m - l)IP} 
L Pr{XR1 = XR1,XT1 = XT1,'" ,XRm = XRm,XTm = xTml P } 
R(m.YR~,YT~) 
XR1 + ... + XRm = YRm,XT1 + ... +XTm = YTm, 
YRk ::::: Rk + 1, YTk ~ Tk - 1, k = 1 ... (m - I)}. 
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The probability of YRm responses at stage m is 
f(m,YRmI P ) = .E f(m,YRm,YTmI P ) 
so we will write 
where 
f(m,YRmI P ) 
= Pr{M = m, YRm = YRmIP} 
= Pr{YRm = YRm,YRk ~ Rk + 1,YTk ~ Tk -l,k = 1··· (m -l)IP} 
.E Pr{XR1 = XR1, ... ,XRm = xRml P } 
R(m,YR=) 
R(m, YRm) = {(XR1,'" ,XRm) : XRl + ... + XRm = YRm, 
YRk ~ Rk + 1, YTk ~ Tk - 1, k = 1· .. (m - I)}. 
Let us examine 
Pr{XR1 = XR1,'" ,XRm = xRmlP} = 
Pr{XR1 = xR1IP}" ·Pr{XRm = xRmlP} 
since the observations in each stage are independent. 
Specifically, we will consider Pr{XRm = xRmlP} from anyone stage. 
PR = Pn + PlO =? 






The summation is 1 because we are summing over all possible values of a multinomial distribution 
with parameters nm - XRm, (I~~R)' and (I~~R)' This shows that the marginal distribution of a 
multinomial is a binomial distribution, which is required to simplify the calculations in the next 
step. 
If we plug the result from Equation 17 into Equation 16, then 
f(m,YRmI P ) 
R(m,YRm) 
nIl 
"""' . pXRl (1 _ PR)(n,-xR,) ... ~ (nl - XRl)!XRl! R 
R(m,YRm) 
n m ! pXRm(1_ P )(nm-XRm) 
(nm - XRm)!XRm! R R 
This is a similar situation to that described by Jung and Kim (2004). Thus it seems 
reasonable to evaluate the resulting estimator with the additional restriction caused by the toxicity 
monitoring. The specific estimator under consideration is 
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where the summations in the numerator and the denominator are over 
R(m, YRm) = {(XR1,'" ,XRm) : XRl + ... + XRm = YRm, 
YRk ~ Rk + 1, YTk ~ Tk - 1, k = 1 .. · (m - I)}. 
In other words, the trial can be stopped early for either toxicity or response considerations which is 
reflected in the additional restrictions. 
The derived point estimator cannot be applied when the Simon 2-Stage design is combined 
with the continuous toxicity monitoring. The stage-wise sample sizes are one and the response is 
either a one or a zero. In either case, (~) = (i) = 1 and the proposed point estimator is not 
applicable. Therefore, we propose to modify the UMVUE by ignoring the toxicity monitoring or 
just applying the estimator proposed by Jung and Kim (2004). The specific estimator is 
where 
YRk ~ Rk + 1, k = 1 ... (m - I)}. 
5.2 UMVUE Proof 
The proof that this is the UMUVE starts with the probability mass function of m and YRm 
which is 
f(m,YRmI P ) 
We will write as 




w= U Wm 
m=l 
The statistic (m, YRm) is sufficient by the factorization theorem. 
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Now, we prove the completeness of (m, YRm). In a manner similar that used by Jung and 
Kim, consider h(PR) = EPR {g(m, YRm)} which is obtained as 
K 
L 
m=l YRm.=rTn-l +1 
K 
L (18) 
m=l YRrn=rTn _l+l 
Now, we need to show that h(PR) = 0 for p E [0,1] => g(m,YR) = 0 for all (m,YR) E (M, YR). 
Define 00 to be 1. If PR = 0, then, from Equation 18 we have g(l, 0) = O. If 1- PR = 0, then, from 
Equation 18 we have g(l,n) = O. Now, for PR E (0,1) let Pj(PR) = h(PR)/Ph and 
Ql(PR) = h(PR)/(l - PR)I. Each term, say term i, in Equation 18 has the factor Pli (1- PR)li for 
some nonnegative integers ji and li. Since all the terms have different factors (ji,li) 1= (jj,lj) if 
i 1= j, any subset of the terms in Equation 18 has a unique minimum either among the j/s or the 
li'S. If j/s have a unique minimum j, then since Pj(PR) = 0 for all p E (0,1), letting p ~ 0 shows 
g(m,YR) = 0 where g(m,YR) is the coefficient of the term with Ph factor. Otherwise, if li'S have a 
unique minimum l, then since Ql(PR) = 0 for all p E (0,1), letting p ~ 1 shows that g(m,YR) = 0 
where g(m, YR) is the coefficient of the term with (1 - PR)1 factor. Whichever coefficient is 0, we 
remove that term from h(PR) before the next step. Starting with j = 1 and l = 1, we continue this 
procedure until all the terms in Equation 18 are removed, concluding that g(m, YR) = 0 for all 
Since (m, YRm) is the complete and sufficient statistic and PRl = XRl/nl is unbiased, by 
the Rao-Blackwell theorem the UMVUE of PR is given by PR = E {X Rli (m, Y Rm)}. If m = 1, we 
have PR = PRl, but if 2 :::; m :::; K, then the conditional probability mass function of XRl given 
(m, YR) in w is 
Pr{XRl = XR1, M = m, YRm = YRm} 
Pr{M = m, YRm = YRm} 
Pr{XRl = XRl, YRm = YRm, ak :::; YRk, k = 2, ... , m - liP} 
f(m,YRmI P ) 
" ( nl ) pXRl (1 _ PR)n1 -XRl ••. ( nm ) pXRm (1 _ PR)nm -XRm L..R(m,YRmlxRl) XRl R XRm R 
f(m,YRmI P ) 
where the summations in the numerator are over 
R(m, YRmlxRl) = {(XR2,··· ,XRm) : XR2 + ... + XRm = YRm - XRl, 
YRk :::: Rk + 1,YTk :::; Tk - 1, k = 1··· (m - I)}. 
The conditional probability simplifies to 
(xn;J L:R(m,YRmIXRd (Xn;2) ... (XnR:) 
L:R(m,YRm) (xn;J ... c::) 
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Therefore, 
PR = E{XRlI(m, YR)} 
nl 
LXRl X Rl (Xr;:') LR(m,YRmIXR,) (X~,) ... (x::J 
nl LR(m,YRm) (xn;,) ... CnR:J 
where the summations in the numerator and the denominator are over 
R(m, YRm) = {(XRl, ... , XRm) : XRl + . " + XRm = YRm, 
YRk :::: Rk + 1, YTk S Tk - 1, k = 1· .. (m - I)}. 
5.3 Simulations 
A series of simulations was constructed to compare the bias and the relative efficiency of 
the proposed estimator to the maximum likelihood estimator (MLE). The relative efficiency is the 
ratio of the mean squared error of the MLE to the variance of the proposed estimator. We 
considered three different clinical trial designs that include both response and toxicity; the Bryant 
and Day (1995) design, the Ray and Rai (2011b) design, and the Simon 2-Stage design combined 
with continuous toxicity monitoring (CTM) (Ivanova et al., 2005; Ray and Rai, 2011a). The 
Bryant and Day methodology is a two-stage design that considers both response and toxicity at 
the same time. The Ray and Rai design is able to examine both response ant toxicity. The toxicity 
examination is performed four times while the response is only examined twice. The final design 
we consider is a Simon 2-Stage design combined with a continuous toxicity monitoring originally 
proposed by Ivanova et al. (2005) but expanded by Ray and Rai (2011a). 
An effort was made to ensure the parameters input into the various clinical trial designs 
were similar while considering the required sample sizes. The design parameters used in the 
simulations are listed in Table 9. Each design requires slightly different specification of the input 
criteria. For instance, the Bryant and Day design requires specification of the unacceptable 
"non-toxicity" rate under the null and the acceptable "non-toxicity" rate under the alternative. 
Table 9 reports these as (1 - P {non-toxicity} ), which is the probability of toxicity under the null 
and alternative hypothesis. In order to simplify the discussion of the simulation results, the designs 
will be grouped based on the response rates used to create the design: 
• Design I - (PRO, PRA) = (0.10,0.30) 
• Design II - (PRO, PRA) = (0.20,0.40) 




Methodology Design PRO PRA P TO PTA OR OT 
° 
f3 
Bryant & I 0.10 0.30 0.40 0.25 0.05 0.05 0.10 
Day II 0.20 0.40 0.40 0.25 0.05 0.05 0.10 
III 0.30 0.50 0.40 0.25 0.05 0.05 0.10 
Ray & I 0.10 0.30 0.33 0.25 0.05 0.05 0.10 
Rai II 0.20 0.40 0.33 0.25 0.05 0.05 0.10 
III 0.30 0.50 0.33 0.25 0.05 0.05 0.10 
Simon 2 I 0.10 0.20 0.33 0.05 0.05 0.10 
Stage II 0.20 0.40 0.33 0.05 0.05 0.10 
with CTM III 0.30 0.50 0.33 0.05 0.05 0.10 
The simulations were repeated for many different values of response, which varied from 0 
to PRA + 0.10 by 0.01 increments. The toxicity rate was always set in the alternative region, since 
stopping early for toxicity will produce similar results to stopping early for futility. The simulation 
procedure for each design was repeated three times to account for three different values of 
correlation between toxicity and response. We consider the smallest possible correlation, a 
correlation of 0, and the maximum possible correlation. The effect of the correlation on the 
simulation results is negligible, so only the results associated with independence are reported here. 
The critical values and sample sizes are reported in Table 10. Each simulation was repeated 10,000 
times where one simulation is an executed clinical trial. 
The proposed estimator is similar to the Jung and Kim (2004) estimator when toxicity and 
response are monitored at the same time. It also important to note that it is not possible to use 
the proposed estimator in the design with the continuous toxicity monitoring. The methodology 
monitors the toxicity after each patient is enrolled. or ni = 1 for i in 1,2, ... ,n. The calculations 
were performed as if the trial was only a two stage design. So if the trial stopped before the first 
response evaluation, then the stage is set to 1 in the expression for the point estimate. If the trial 
stopped before the end of the trial but after the first Simon 2-Stage boundary, then the stage was 
considered the second stage. 
Figure 16 displays the bias of the MLE over the range of possible response rates, which 
includes PRO and PRA. The bias of the MLE is the largest near PRo instead of near the extreme 
values 0 or PRA + 0.10. We can also see the additional stopping for toxicity induced by the Ray 
and Rai design creates a slightly different pattern in the bias of the MLE. 
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TABLE 10 
Sample Sizes and Critical Values 
Sample Response Toxicity 
Methodology Design Sizes Boundaries Boundaries 
nl n Tl T tl t2 
Bryant & I 41 100 5 14 26 67 
Day II 37 103 8 27 23 69 
III 39 95 12 35 24 64 
nl = n2 = 
n3 = n4 n Tl T tl t2 t3 t4 
Ray & I 11 44 3 7 7 13 20 22 
Rai II 13 52 6 13 9 19 19 24 
III 14 56 9 22 10 16 25 25 
nl n Tl T tl,t2, ... ,tn 
Simon 2 I 18 35 2 6 See Table 11 
Stage II 19 54 4 15 See Table 11 
with CTM III 24 63 8 24 See Table 11 
The absolute value of the bias of the MLE is the largest when it is used with the Simon 2-Stage 
design combined with continuous toxicity monitoring. 
Figure 17 depicts the bias of the proposed estimator, which includes the modified estimator 
utilized for the Simon 2-Stage design with continuous toxicity monitoring. In each case, we can see 
there is not an obvious pattern. The bias is near 0 in each simulation. The maximum reduction in 
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Figure 17. Bias of Proposed (or Modified) Estimator 
The relative efficiency of the MLE to the proposed estimator is pictured in Figure 18. The 
MLE is more efficient than the new estimator near the value PRO in the Bryant and Day, as well as 
the Simon 2-Stage design combined with the continuous toxicity monitoring. The proposed 
estimator is more efficient in all situations when the response rate is larger than PRO, but not quite 
as large as PRA. The MLE is the most efficient when the responses rates are small in the Ray and 
Rai design. The curve is also bimodal, in two of the three general design categories, utilizing this 
methodology. 
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Figure 18. Relative Efficiency of the Maximum Likelihood Estimate to Proposed (or 
Modified) Estimator 
The performance of the modified estimator in the continuous toxicity monitoring situation 
is good. The bias is small across the range of response rates. Also, the proposed estimator is more 
efficient than the MLE over portions of the range of the response rates. Next, we consider the 
benefit of incorporating the additional information from the toxicity monitoring into the estimator. 
Figure 19 graphs the relative efficiency of the proposed estimator to the modified version of the 
estimator in the Ray and Rai design. The relative efficiency is examined through the ratio of the 
mean squared error of the modified estimator to the variance of the proposed estimator. We can 
see for response rates larger than 0.10 the proposed estimator is more efficient than the modified 
version that only incorporates information from two of the four stages. Thus, the new estimator is 
more efficient but one could also use the modified version since it reduces the bias when compared 
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to the MLE. 
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Figure 19. Relative Efficiency of Modified Estimator to Proposed Estimator in the 
Ray and Rai Design 
5.4 Discussion 
The investigation was conducted to determine the best estimator to use after a clinical trial 
that leveraged the Simon 2-Stage design with the continuous toxicity monitoring methodology. We 
found an estimator that can be utilized in bivariate designs that stop early for either response or 
toxicity. We also showed that the new estimator is the uniformly minimum variance unbiased 
estimator. We then modified the estimator so it could be used with continuous toxicity monitoring. 
Through simulation we discovered that it is also an unbiased estimator, but the proposed 
estimator is more efficient over specific ranges of the response rate. 
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TABLE 11 
Continuous Toxicity Monitoring Boundaries - Design I, II, and III 
Design I Design II Design III 
PTa = 0.33, aT = 0.05, n = 35 PTa = 0.33, aT = 0.05, n = 54 PTa = 0.33, aT = 0.05, n = 63 
# of # of # of 
Minimum Maximum Subjects Minimum Maximum Subjects Minimum Maximum Subjects 
# # with a # # with a # # with a 
Subjects Subjects Toxicity (ti) Subjects Subjects Toxicity (t;) Subjects Subjects Toxicity (ti) 
4 4 4 4 4 4 4 6 5 
5 5 5 5 5 5 7 7 6 
6 7 6 6 7 6 8 8 7 
8 9 7 8 9 7 9 11 8 
10 12 8 10 11 8 12 12 9 
13 14 9 12 13 9 13 15 10 
15 16 10 14 15 10 16 17 11 
17 18 11 16 17 11 18 20 12 
19 20 12 18 20 12 21 22 13 
21 22 13 21 22 13 23 24 14 
23 24 14 23 24 14 25 26 15 
25 27 15 25 26 15 27 28 16 
28 29 16 27 29 16 29 31 17 
30 31 17 30 31 17 32 33 18 
32 32 18 32 33 18 34 35 19 
33 35 19 34 35 19 36 38 20 
36 38 20 39 40 21 
39 40 21 41 42 22 
41 43 22 43 45 23 
44 44 23 46 47 24 
45 47 24 48 50 25 
48 50 25 51 52 26 
51 52 26 53 54 27 
53 54 27 55 57 28 
58 59 29 
60 61 30 
62 63 31 
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CHAPTER 6 
PHASE lIB OR III CLINICAL TRIAL DESIGNS THAT 
INCLUDE MULTIPLE ENDPOINTS 
The phase III or lIb clinical trial is typically a large randomized study intended to confirm 
the efficacy observed earlier in the treatment development process. The patients are randomized 
into at least two arms, but the designs may include three or more arms as well. The designs often 
include provisions for early examination of the data using group sequential theory. The early 
methodologies by Pocock (1977), as well as O'Brien and Fleming (1979), allow early termination of 
the trial if there was evidence to reject the null hypothesis. Other authors, such as Emerson and 
Fleming (1989), consider group sequential procedures that allow the trial to terminate early in 
favor of or to reject the null hypothesis. Jennison and Turnbull (1999) refer to these as 
"inner-wedge" designs since the futility stopping boundaries form a wedge inside of the efficacy 
boundaries. The designs focus on univariate normally distributed variables, such as clinical 
response or event free survival. 
Halperin et al. (1982) propose a method that allows a study to terminate early for futility 
based on stochastic curtailment, which is a flexible approach to monitor the emerging results of a 
clinical trial. Lachin (2005) describes stochastic curtailment as a decision to terminate the trial 
based on an assessment of the conditional power (CP). CP is the conditional probability that the 
final result will exceed the critical value given the accrued data and an assumption about the data 
to be observed during the remainder of the study. Ying and Clarke (2010) outline a flexible 
time-varying conditional power boundary methodology, which allocates portions of the type II 
error over time based on the typical alpha-spending functions. The methodology has similar 
benefits including the ability to pre-specify the interim analysis. One could also use the flexibility 
associated with the alpha-spending approach to modify the exact timing of the interim analysis. 
The resulting methodology is an intuitive expansion and application of the conditional power 
approach to futility monitoring. 
The safety of the clinical trial subjects is an important endpoint that must be considered 
in all clinical trials. According to the ICH E9 guidelines on Statistical Considerations in Clinical 
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ThaIs, safety must be monitored in all clinical studies (Chow and Liu, 2004). The studies should 
incorporate procedures that allow for early termination of the trial for safety reasons. There are 
two different types of bivariate test procedures which can include multiple stages. One could 
formulate a test procedure which uses a global test statistic such as Hotelling's t-test (Hotelling, 
1931). It is also possible to construct a test procedure that considers the marginal endpoints 
separately. Jennison and Turnbull (1993), as well as Cook and Farewell (1994), propose bivariate 
test procedures that consider both endpoints separately, but attempts to control the global type I 
and II error rates. The group sequential procedures allow one to evaluate both efficacy and futility, 
as well as patient safety, through the conduct of the trial. There are also more sophisticated 
methods proposed to control the average type I error rate as well. Chuang-Stein et al. (2007) 
suggest a method that attempts to control the average type I error rate resulting in slightly 
different significant levels associated with the marginal hypothesis test. In this chapter, we will 
consider combining the conditional power approach with the customary method proposed by 
Jennison and Turnbull (1993). Currently, it is difficult to allow early termination for only futility 
or safety considerations. 
The fixed sample size design described by Jennison and Turnbull (1993) examines both 
endpoints separately but simultaneously. The usual critical value, Zcr., is used to evaluate both 
endpoints in separate tests where both null hypothesis much be rejected to declare the treatment 
successful. The sample size required to achieve the power, 1 - (3, relies on the joint bivariate 
normal (BVN) distribution, including the correlation between the test statistics. The overall type I 
error rate maybe much smaller than expected, resulting in a much more conservative trial than 
desired, especially in the phase lIb clinical trial setting. In Section 6.1, we describe the fixed 
sample size test in detail including the potential issue with the overall type I error rate. We then 
propose a modification which searches for a critical value, C, and corresponding sample size that 
controls the overall type I and II error rates, respectively. In Section 6.2, we combine both fixed 
sample size methodologies with the time-varying conditional power concept which allows us to stop 
the trial early for either futility or safety. The two fixed sample size methods are examined through 
simulation in Section 6.4. The simulation results associated with the conditional power approach 
combined with the fixed sample size methodologies is discussed in Section 6.5. The conditional 
power combined with the customary fixed sample size approach, that utilizes the critical value, Zcr., 
during the early examinations of the data, inflates the type II error rate. It is found that the type 
II error rate of the customary procedure is controlled if the critical value, C, is leveraged for the 
interim analysis and the critical value, Zcr., is utilized in the final analysis. A final discussion of the 
results is included in Section 6.6. 
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6.1 Fixed Sample Design 
First, we will consider the fixed sample size situation in which subjects can be randomized 
into either a treatment group or a control group. The hypothesis to be evaluated is 
or P TT ~ PTC +OT 
versus (19) 
and PTT < PTC + OT 
where PRT is the response rate from the treatment group, PRC is the response rate from 
the control group, P TT is the toxicity rate from the treatment group, PTC is the toxicity rate from 
the control group, and OT is the increase in toxicity allowed for the new treatment to achieve the 
response rate. The hypothesis test displayed in Equation 19 can also be broken down into the 
marginal hypotheses 
and (20) 
H 2o : P TT ~ PTc + OT versus H 2A : P TT < P TC + OT 
where both HlO and H 2o must be rejected to declare the new treatment successful. Jennison and 
Turnbull (1993), as well as Cook and Farewell (1994), propose methods that control the type I 
error rate for the marginal tests. Then, the procedure searches for a sample size that meets the 
power requirements. 
Let X T = (XRT' XTT) be the mean response and toxicity vector for the treatment group 
and Xc = (XRC, XTC) be the mean response and toxicity vector for the control group. Let 8RT 
and 8 RC be the sample standard deviations for the response measurement from the treatment and 
the control groups, respectively. Also, let 8TT and 8TC be the sample standard deviations for the 
toxicity measurement from the treatment and control groups. Let ZRT = (ZR, ZT) be the 
standardized bivariate test statistic where 
and 
Note that ZRT follows a BV N(O, I;), under the null hypothesis, where 
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Response and toxicity can both be measured as correlated binomial random variables, which have 
asymptotic normal distributions. 
Jennison and Turnbull (1993) control the marginal type I error rates. If the marginal type 
I error rates are controlled at the same a-level, say 0.05, then the true type I error rate of the 
combined test maybe be much smaller than expected. Under the null hypothesis assuming the 
standardized tests statistics are independent, 
P{ZR > Za n ZT > ZalHo} 
P{ZR > ZaIHO}P{ZT > ZalHo} 
P{ZR > Za n Ho} P{ZT > Za n Ho} 
P{ZR > Za} P{ZT > Za} 
P{ZR> Za n (HlO or H20 )} P{ZT > Za n (HlO or H20 )} 
P{ZR> Za} P{ZT > Za} 
P{ZR > Za n HlO } P{ZT > Za n H20 } 
P{ZR > Za} P{ZT > Za} 
P{ZR> ZalHlO} . P{ZT > Za1H20} 
0.05 . 0.05 = 0.0025. 
The type I error rate also depends on the correlation and can vary from 0 to 0.05 as the correlation 
varies from -1 to 1. It is also possible to consider the more general case 
where ZaR is associated with response and ZaT is associated with toxicity. 
Although the marginal hypotheses maybe of interest in some settings, it is also possible 
that the overall type I error rate is too conservative in other instances. Using the numeric 
integration algorithm developed by Genz (2004), it is possible to search for two critical values, CR 
and CT, such that 
In order to reduce the complexity of the discussion, we will consider the case when CR = CT = C 
and only search for a single critical value, C, that satisfies 
P{ZR > C n ZT > CIHo,p}::; a. 
The approach will increase the type I error rate associated with the marginal hypothesis test, but 
will control the overall type I error rate at the specified level for the joint hypothesis. A bisection 
algorithm is used to search for C and the concept could be expanded to more than two endpoints. 
It is also important to note that Zhao, Grambsch, and Neaton (2005) evaluated several bivariate 
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integration algorithms and the Genz algorithm was preferred, since it is accurate and executes 
quickly. 
Once the critical value, C, is determined, then we can search for the sample size that meets 
the required type II error rate. The probabilities under consideration are 
The specific double integral under consideration is 
where 
J(Z Z ) _ 1 (-(Zit- 2PZT ZR+Z:})) R, T - ;:;--:::2 exp . 27ry 1 - p2 2(1 - p2) 
The fixed sample size design will be evaluated in the Section 6.3. 
6.2 futility and Safety Monitoring 
The ability to stop a trial early for futility is extremely important since it prevents future 
patients from receiving an ineffective treatment. The conditional power approach is a popular 
methodology that allows one to predict the ability to reject the null hypothesis given the current 
data along with an assumption about the detect size (Lachin, 2005). Ying and Clarke (2010) note 
that the B-value is often used as a data monitoring tool, which is a function of the sequence of 
standardized test statistics {Zl' Z2, ... , ZK} calculated at information times ti = ni/N for 
1 
i = 1,2, ... ,K. The B-value at information time ti is typically defined to be B(ti ) = Zit;. The 
conditional power at information time ti, assuming no efficacy analysis, is approximated by 
CP(Zi) = 1- <I> (b(l) - Bi(ti) - (1- ti)e) 
01 - ti) (21) 
where <I>(.) is the cumulative distribution function of the standard normal distribution and e is the 
drift parameter. The conditional power is typically calculated with the desired detect size and 
compared to a fix "I, such as 0.5. The trial is stopped early for futility if CP(Zi) < "I. 
Ying and Clarke (2010) propose a flexible method to create a time-varying conditional 
power boundary denoted as "Ii(ti), for i E {I, 2, ... ,K}. The formulation relies on the following 
observations associated with a K interim analysis performed at information times {tl' t2, ... t K}. 
Before the final analysis, "Ii(ti) is determined such that 
(22) 
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for i = 1,2, ... K where f is an increasing function with f(O) = 0 and f(l) = f3 and 
(23) 
The conditional power formulation in Equation 22 can be equivalently expressed in terms of the 
standardized test statistics 
P{ZI - ej(tt) 2: GI , ... , Zi-l - ej(ti-l) 2: Gi- l , Zi - ej(ti) < Gi } = 
f(t i ) - f(t i - l ) 
for i = 1, 2, ... K. The authors note that {ZtVlt - et : 0 S; t S; I} follows a Brownian motion 
process and thus apply the usual alpha-spending functions to the type II error rate to determine 
the futility monitoring constants {GI , G2 , ... ,GK }. 
The same approach can be applied to the marginal hypothesis tests HlO and H 2o described 
in Equation 21, since both must be rejected in order to reject the null hypothesis. If either one of 
the two hypotheses appears to not be able to reject the null hypothesis, then the study should be 
stopped early. In the formulation of the hypothesis H2o, the same concept can be applied to the 
monitoring of toxic events. If it does not appear that the number of toxic events will be less than 
the number experienced on the control treatment plus the margin, then the trial can be stopped 
early as well. Section 6.3 will explore the type I and II error rates resulting from the combination 
of the conditional power approach and the bivariate test procedure. We will also consider two 
different alpha-spending functions. 
6.3 Simulations 
First, we will consider the fixed sample size design discussed in Section 6.1. We will 
consider two different methods to determine the fixed sample size. Method 1 is similar to the 
method described by Jennison and Turnbull (1993) and will use the typical critical values, Z"" for 
the marginal tests. Then we will use the bivariate normal distribution to search for the sample size 
based on the required power. Method 2 will search for the critical values, G, such that the overall 
type I error rate is controlled at the specified level. Then the procedure will search for the sample 
size that controls the type II error rate. We will examine the effects of the correlation on the type I 
and II error rates when it is different than assumed during the design of the trial. The second set 
of simulations will combine Method 1 with the conditional power concept on the marginal 
hypothesis test discussed in Equation 21. We will also consider the conditional power methodology 
for efficacy and safety combined with Method 2. Then we will examine the type I and II error 
rates, as well as the probability of stopping early under different circumstances. The values 
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reported in the subsequent tables are based on 100,000 simulations, or each error rate reported is 
an average based on 100,000 simulated clinical trials. 
6.4 Simulation - Fixed Sample Size 
The clinical trial utilized in the simulation is designed to detect a 0.20 increase in response 
rate, as well as a toxicity rate that is no more than 0.20 larger than the control. For proposes of 
the simulation and calculations, we assume a response rate of 0.30 and toxicity rate 0.30 for the 
standard treatment. We will set the marginal type I error rates at 0.05 and the overall power at 
0.80. The only way we can make a type I error under the null is if we reject the null hypothesis for 
both endpoints. The overall type I error rate for Method 2 will be fixed at 0.05, and then we will 
search for the critical value that produces the result. The current setup assumes equal allocation of 
subjects between the treatment and the control. 
Table 12 contains the sample sizes and critical values required to control the type I and II 
error rates for the specific hypothesis described above. We can see that the sample size decreases 
as p increases in Method 1. We can also see that the critical values, C, and sample sizes increase in 
Method 2 as the correlation increases. 
TABLE 12 
Sample Sizes and Critical Values 
Method 1 Method 2 
Correlation Critical Value Sample Size Critical Value Sample Size 
-80% 1'.645 190 0.163 46 
-60% 1.645 190 0.334 58 
-40% 1.645 188 0.485 70 
-20% 1.645 188 0.625 80 
0% 1.645 186 0.760 90 
20% 1.645 182 0.894 100 
40% 1.645 178 1.030 110 
Once the critical values and the sample sizes are calculated with a specified p, then we 
consider the effect of incorrectly specifying the correlation on the type I and II error rates. Table 
13 contains the simulated power based on different values of p when independence is assumed to 
design the trial. The correlation will not take on the full range of [-1, 1] in this instance due to the 
underlying multinomial distribution associated with the various combinations of response and 
toxicity. 
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We can see that the power increases as p increases from the minimum value of -80%. We can also 
see that power is achieved when p = 0 but is less than desired when the correlation is negative. 
TABLE 13 
Simulated Power and Type I Error Rate Under Various Correlations When Assumed 
to be Independent 
Method 1 Method 2 
Type I Type I 
Correlation Error Rate Power Error Rate Power 
-80% 0.000% 79.611% 0.004% 78.639% 
-60% 0.001% 79.724% 0.542% 78.966% 
-40% 0.014% 79.814% 1.603% 79.102% 
-20% 0.091% 80.088% 2.955% 79.350% 
0% 0.221% 80.670% 4.556% 80.011% 
20% 0.478% 81.544% 6.431% 80.895% 
40% 0.915% 82.309% 8.622% 81.812% 
The effect of the correlation on the type I error rate is also available in Table 13. In 
general, we can see that the simulated type I error rate for Method 1 is much smaller than for 
Method 2. We can also see that the type I error rate increases as p increases in both methods. The 
simulated type I error rate exceeds the specified alpha-level in Method 2, but achieves a maximum 
value of 0.915% in Method 1. 
The final item to consider is the simulated type I error rate when we reject one of the two 
hypotheses, but fail to reject the other. For instance, does the type I error rate increase if we reject 
HlO but fail to reject H2o , Table 14 contains the results of the simulation when we reject one of 
the hypotheses but fail to reject the other. We can see that the resulting type I error rates are all 
less than 5% for Method I but nearly 20% for Method 2. 
TABLE 14 
Type I Error Rate When One Endpoint Falls in the Rejection Region and The Other 
Does Not 
Hypothesis Hypothesis Type I Standard 
Rejected Not Rejected Error Rate Error 
Method 1 HlO H2o 4.73% 0.067% 
Method 2 HlO H2o 18.68% 0.123% 
Method 1 H2o HlO 3.94% 0.062% 
Method 2 H2o HlO 19.39% 0.125% 
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Both designs can be used to examine response and toxicity at the same time. The reduced 
sample size in Method 2 creates an additional cost associated with the type I error rate, if we are 
able to reject only one of the two hypothesis. Next we will add in monitoring that allows the trial 
to terminate early for either efficacy or safety. 
6.5 Simulation - Conditional Power 
The time varying conditional power approach requires one to specify an alpha-spending 
function, the type II error to be spent, and the number of interim analysis. In the simulations we 
investigate the Pocock and the O'Brien-Fleming type boundaries combined with Method 1 and 
Method 2. We consider 3 examinations before the end of the trial that allow one to stop early for 
futility or safety. At the end of the trial we only allow rejection of the null hypothesis. Rejection 
requires both HlO and H 2o to be rejected in order to declare the treatment successful. 
The fixed sample sizes associated with independence are used in the simulations. The 
simulations are designed to repeat each clinical trial 100,000 times. Initial investigations 
demonstrated an inflation of the type II error rate, if we created the conditional boundary values 
based on the full power. The conditional boundary values are constructed with 50% of the 
specified type II error, and then it is equally allocated to each end point. This is similar to a 
Bonferroni correction in the usual multiplicity problem. The result is boundary values based on a 
type II error rate of 5% per endpoint point. 
The decision rules applied to the ith analysis for i = 1,2,3,4 are: 
1. At time ti for i < 4, calculate CP(8) based on the accumulated data and the desired effect 
size for each endpoint. If CP(8) S 'Yi for either end point, then stop the trial for either 
safety or futility; 
2. else, continue the trial and repeat step 1 for i < 4; 
3. at the final analysis, if ZR > C and ZT > C, where C is the appropriate critical value, then 
we declare the treatment successful; otherwise we cannot reject the null hypothesis. 
Table 15 provides the conditional power boundary values used in the simulation. We can 
see that the Pocock type boundary is much larger early in the trial than the O'Brien-Fleming type 
design. This is similar to the alpha-spending approach, since the Pocock type boundary will have a 
much higher probability of stopping very early when compared to the O'Brien-Fleming boundary 
values. 
The probability of stopping at each stage is displayed in Table 16. We can see that the 
probability of stopping early under the null hypothesis is very high in Method 1 for both the 
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TABLE 15 










O'Brien-Fleming and the Pocock type boundaries. The probability of stopping early under the 
alternative is also very large for both boundary value types, which will increase the overall type II 
error rates. The simulated type II error rates are reported in Table 17. We can see the simulated 
type II error rate is 29.16% with the O'Brien-Fleming boundary values and 60.43% with the 
Pocock boundary value types. It appears aggressive monitoring using the conditional power 








Percentage of Trials That Stopped Early 
1_ Under the Null Hypothesis 1 Under the Alternative Hypothesis 1 
Stage Method 1 Method 1a Method 2 Method 1 Method 1a Method 2 
1 67.48% 5.63% 6.60% 9.55% 0.08% 0.46% 
2 25.67% 35.35% 34.84% 8.52% 0.50% 3.07% 
3 4.70% 31.00% 30.12% 2.57% 0.50% 3.69% 
Total 97.85% 71.98% 71.56% 20.64% 1.08% 7.22% 
1 96.98% 36~46% 36.49% 55.38%--- 2.79% 6.99% 
2 1.56% 22.02% 22.01% 1.41% 0.60% 2.71% 
3 0.48% 9.96% 11.98% 0.27% 0.12% 1.15% 
Total 99.02% 68.44% 70.48% 57.19% 3.51 % 10.85% 
TABLE 17 























Method 2 utilizes the sample sizes and critical values from Table 12 corresponding with 
independence. In Table 16, we can see that the total probability of stopping early for either futility 
or safety is at most 71.56% under the null hypothesis. The Pocock type boundary values stop at 
the first analysis 36.46% while the O'Brien-Fleming type only stops at the first stage 6.60%. The 
percentage of clinical trials terminating early increases for the O'Brien-Fleming method but 
decreases for the Pocock method. The simulated type II error associated with the O'Brien-Fleming 
and Pocock boundary values are 19.37% and 23.04%, respectively. The Pocock type boundary also 
results in a slightly more conservative trial with a simulated type I error rate of 3.91% while the 
simulated type I error rate of the O'Brien-Fleming is 4.57%. 
Method 1a is a modification of the calculation of the conditional power associated with 
Method 1. Method 1a replaces b(l) = Zo: in equation 20 with the critical value, C, from Table 12 
associated with Method 2. The critical value, C, from Table 12 is the critical value used to 
evaluate the joint hypothesis. The probability of stopping early under both the null and 
alternative hypothesis for Method 1a is similar to Method 2. The simulated type I and II error 
rates reported in Table 17 are also similar to the error rates for Method 2. 
It is possible to construct conditional boundary values in various ways but it is suggested 
that simulations be performed to evaluate the designs. For instance, we considered creating 
O'Brien-Fleming boundary values for Method 1 with marginal beta set at 2.5% which results in 
conditional power boundaries 'Yi = (0.1209,0.0932,0.0385). The resulting probability of stopping at 
Stage 1 is 39.65%, Stage 2 is 42.11%, and Stage 3 is 11.99%. The total percentage of stopping is 
93.75%. The simulated type I error rate is 0.222% while the type II error rate is 22.67%. The 
results are similar to the type I and II error rates of the fixed sample size design. Only 10.04% of 
the clinical trials stopped early under the alternative hypothesis. 
6.6 Discussion 
The bivariate test procedure allows one to design a trial that considers both endpoints 
simultaneously while controlling the overall type I and II error rates. Method 1 controls the type I 
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error when one endpoint falls in the rejection region while the other endpoint does not, but also 
requires a larger sample size. Method 2 requires a smaller sample size, but the type I error rate 
will be inflated if one endpoint is rejected while the other is not. Also, the overall type I and II 
error rates will be affected by misspecification of the correlation. It is important to evaluate the 
sample sizes and critical values, under different assumptions, to understand the characteristics 
before they are used in practice. 
The conditional power applied to both endpoints allows one to stop the trial early for 
either futility or safety. The choice of alpha-spending function and the amount of type II error rate 
to allocate drastically affects the overall type II error rate. The choice of alpha-spending function 
also affects the probability of stopping early under the null or alternative hypothesis. The choice 
also affects the overall type I and II error rates. Method IC preserves the type I error rate if one of 
the hypotheses is rejected. It also preserves the type II error rate while allowing early 
examinations for both futility and safety. The method could be used with the ideas proposed by 
Chuang-Stein et al. (2007). It is important to note that the design should be evaluated through 
simulations before it is implemented in order to fully understand the operating characteristics. 
In the end, the bivariate design fills a unique need that consider both endpoints 
simultaneously that controls the over type I and II error rates. The inclusion of the conditional 
power approach allows one to also examine the data early and make appropriate decisions 




The requirement to monitor the safety of the clinical trial's subjects in the phase II and III 
studies motivated the dissertation research. Phase II and III clinical trials primarily focus on the 
efficacy of the new treatment. The trials are specifically designed to evaluate the response of the 
new drug treatment or the various survival rates. The safety of the participants cannot be 
neglected. 
7.1 Concluding Summary 
In practice, the clinical studies are designed to evaluate the primary endpoints. The 
toxicity considerations are included in an ad hoc manner outside of the formalized design. The 
motivating example designed a trial utilizing the same approach. First, the sample sizes and 
critical values were determined based on the Simon 2-Stage design. Then the toxicity was 
monitored after each patient was treated, utilizing the continuous toxicity monitoring methodology. 
At the time the trial was designed, the operating characteristics of the combined procedure 
were unknown but required to evaluate the resulting design. Recursive expressions that accurately 
describe operating characteristics were discovered. The expressions assumed an underlying 
multinomial distribution. The operating characteristics include the type I and II error rates, the 
probability of early termination (PET), and the average sample size (ASN). 
The theoretical expressions of the operating characteristics associated with the combined 
procedure unlocked many possibilities. First, we discovered the effect of the correlation between 
response and toxicity on the type I error rate. As the correlation increases the overall type I error 
rate decreases, or the combined procedure becomes more conservative. We also discovered an 
optimal choice for the type I error rate associated with the toxicity monitoring, or it should be set 
at 5%. 
The decrease in the overall type I error rate of the combined procedure was disconcerting 
but a consequence of the ad hoc methodology. The combined procedure assumes that response and 
toxicity are independent, which may not necessarily be true. There is no way to fix the assumption 
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since the trial is designed in two steps. Therefore, the expressions for the operating characteristics 
were leveraged to create a flexible, bivariate clinical trial design that can monitor toxicity on a 
different schedule than response. The flexible design can include the simple bivariate two-stage 
design or the continuous toxicity monitoring methodology that examines response twice. 
An example design that monitors toxicity four times and response twice, at the second and 
forth toxicity monitoring, was constructed and evaluated through simulation. The design is able to 
control the overall type I and II error rates. The type I error rate is inflated when one endpoint is 
in the null and the other is in the alternative. The issue is caused by the limited sample sizes 
expected in the phase II clinical trial setting. The result is also similar to other bivariate phase II 
clinical trial designs proposed by Conaway and Petroni (1995), as well as Bryant and Day (1995). 
Also, the type I error rate may be larger than expected if the true correlation is smaller than 
specified. 
The next topic to consider was proper inference after the conduct of the bivariate, 
multiple-stage clinical trial. The maximum likelihood estimate (MLE) was found to be biased due 
to the multiple examinations of the response and toxicity. A uniformly minimum variance unbiased 
estimator (UMVUE) was discovered, which successfully removed the bias over the range of possible 
response rates. The point estimator had to be modified to work in the combined procedure, but 
the estimator preserved the reduction in bias. We also learned that the UMVUE is more efficient 
than the modified estimator, so the information associated with toxicity should not be ignored. 
Finally, the natural extension of the research led to multiple-stage, bivariate clinical trials 
utilized in the phase lIb or III setting. The phase lIb/III clinical trials are typically multiple-arm 
and require larger sample sizes. The multivariate normal distribution is applicable in the 
comparative trial. Therefore, the methods proposed by Jennison and Turnbull (1999) were 
combined with the stochastic curtailment. The reverse multiplicity issue was addressed with a 
Bonferroni type correction to preserve the overall type II error rate. The stochastic curtailment 
also required a new critical value to be utilized. The new critical value prevented inflation of the 
type II error rate caused by the repeated hypothesis testing. 
In summary, the toxicity considerations were formally incorporated into the clinical trial 
designs. Appropriate inference procedures were developed so that point estimation and other 
analytics can be performed after the conclusions of the studies. The research conducted to this 
point is an attempt to make clinical trial designs that formally include toxicity and response more 
appealing to biostatisticians, as well as principal investigators. 
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7.2 Future Research 
The results presented previously expand the bivariate multiple-stage designs in an attempt 
to make them more appealing in practice. Although we have made many significant advancements, 
additional work must be completed. 
The flexible, bivariate multistage clinical trial design searches over a multinomial 
distribution in a similar manner to the Conaway and Petroni (1995) methodology. Although the 
algorithm functions on a computer cluster, it will not execute in a reasonable time on a personal 
PC. It seems reasonable that the search algorithm can be improved through intelligent selection of 
the starting values. R is currently used to perform the search algorithm, but a precompiled 
language, such as C+ or Fortran, might be a better choice. If this problem is solved, it will also 
make the design more accessible. 
Inference after the conclusion of single-arm, mutlistage, bivariate clinical trials also requires 
additional attention. Unbiased point estimation is an improvement over the maximum likely 
estimates, but additional research is required. Principal investigators and biostatisticians require 
confidence intervals, as well as p-values. The confidence intervals involve an evaluation of the 
coverage probabilities. The creation of the p-values requires an ordering of the sample space, which 
includes consideration of the toxicity monitoring. 
Finally, the bivariate phase lIb or III clinical trial is only the first component of the 
research in this area. The initial design assumes that both endpoints are binomial, but the phase 
III clinical trial is usually designed to evaluate various survival rates. The current design, including 
the conditional power approach to interim analysis, can be applied in the situation that considers a 
survival probability and the binomial for toxicity. The design can also accommodate the same 
flexibility available in the phase II setting. The research should modify the multiple-arm, 
multiple-endpoint design so it can monitor toxicity on a different schedule than response. Finally, 
an unbiased estimator should be available in the multiple-stage, multiple-endpoint comparative 
clinical trial. 
The proposed research represents future work that would improve the safety of the 
subjects while also ensuring the overall type I and II error rates are not sacrificed. The designs 
could also include adaptive features that, for example, estimate the correlation between response 
and toxicity based on available data; then the procedure modifies the sample size accordingly. The 
future research must also reflect the methods used in practice. The work will be directly influenced 
by current applications of statistical methods and may include considerations for patient 
heterogeneity based on emerging genetic methods. 
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